

NATIONAL LIST OF ESSENTIAL MEDICINES NEPAL

SEVENTH REVISION

2026

Government of Nepal
Ministry of Health and Food Safety
Department of Drug Administration

Government of Nepal
Ministry of Health and Food Safety
Singhadurbar, Kathmandu, Nepal.
Phone No. 4262590
4262802
4262706
4262935
4262862
4223580

Ref No.:



MESSAGE

It is with great pleasure that I acknowledge the publication of the "Seventh Edition of the National List of Essential Medicines (NLEM) 2026" by the department of Drug Administration, Ministry of Health and Food Safety. This important update represents a significant advancement in our ongoing efforts to strengthen the quality, consistency, and efficiency of healthcare service delivery across public health facilities, particularly through improved supply and management of essential medicines.

The NLEM remains a key policy instrument in promoting rational use of medicines and ensuring equitable access to safe, efficacious, quality-assured, and affordable pharmaceuticals. Its effective implementation will conttribute substantially to enhancing health ssystem performance and advancing the constitutional commitment to the right to health, in alignment with the country's evolving disease burden and public health priorities.

I strongly encourage all healthcare professionals to diligently utilize this revised list in their clinical practice. I also urge all government health institutions to systematically integrate the NLEM into their procurement systems and service delivery frameworks, thereby ensuring its effective and sustained implementation.

I extend my sincere appreciation to the experts, partners and stakeholders from various disciplines whose valuable contributions have enriched this revision. I also commend the Department of Drug Administration and all those involved for their dedication and hard work in successfully completing this important publication.

.....

Dr. Bikash Devkota
Secretary
Ministry of Health and Food Safety

Government of Nepal
MINISTRY OF HEALTH AND FOOD SAFETY
DEPARTMENT OF DRUG ADMINISTRATION
1748, Madan Bhandari Path-4
Bijuli Bazar, Kathmandu

Ref. No.: .....

PREFACE



The World Health Organization (WHO) defines essential medicines as those that satisfy the priority healthcare needs of the population. These medicines are selected based on their public health relevance, proven efficacy and safety, and comparative cost-effectiveness. A judicious selection of a limited range of essential medicines is fundamental to strengthening health systems by improving the quality of care, enhancing medicine management, ensuring efficient supply chains, promoting rational use, and improving overall affordability and accessibility.

In Nepal, the Government of Nepal, through the Department of Drug Administration (DDA), first introduced the National List of Essential Medicines (NLEM) in 1986. Since then, the list has undergone periodic revisions to reflect evolving public health needs and advances in medical science. The present document, the *Seventh Revision of the National List of Essential Medicines (NLEM 2026),* has now been duly approved marking a significant milestone in Nepal's efforts to strengthen equitable access to essential medicines.

This revision has been developed in full alignment with the objectives of the National Drug Policy, 1995, which seeks to ensure the availability, affordability, efficacy, safety, and quality of medicines in a sustainable and equitable manner, while also promoting the rational use of medicines among healthcare professionals and the public.

The NLEM 2026 has been updated in reference to the latest WHO Model List of Essential Medicines (2025) and incorporates 436 medicine molecules across a wide range of therapeutic categories. The revision process was undertaken through extensive and inclusive consultations with clinical specialists, professional medical societies, associations, government programme managers, academia, and relevant national and international stakeholders.

I would like to express my sincere appreciation to all experts and stakeholders whose valuable insights and dedicated engagement made this revision possible. Their collective expertise has been instrumental in ensuring that the NLEM remains responsive to the country's priority health needs.

I am also profoundly grateful to the World Health Organization Nepal and Helen Keller International Nepal for their continued technical support throughout the revision process.

It is my sincere hope that this updated NLEM 2026 will serve as a vital reference for healthcare providers, guiding rational prescribing and effective medicine management across all levels of the health system. Full adoption of this list, particularly within the public health sector, will contribute significantly to improved health outcomes and the advancement of universal health coverage in Nepal.

1st Sept 2026

.....

Bharat Bhattarai
Director General
Department of Drug Administration

ACKNOWLEDGEMENT

We would like to express sincere gratitude to all those who contributed to the revision process of the National List of Essential Medicines (NLEM) 2026. This important undertaking would not have been possible without the dedication, expertise, and collaborative spirit of the individuals and institutions involved. We would like to acknowledge the leadership and guidance of:

- **Mr. Bharat Bhattarai,** Director General, Department of Drug Administration, MoHFS
- **Mr. Narayan Prasad Dhakal**, Chief Drug Administrator, MOHFS
- **Ms. Shiwani Khadgi**, Senior Drug Administrator, Department of Drug Administration, MoHFS
- **Mr. Pramod KC**, Former Senior Drug Administrator, Department of Drug Administration, MoHFS
- **Mr. Kiran Sunder Bajracharya**, Senior Drug Administrator, Department of Drug Administration, MoHFS
- **Mr. Mukendra Panjiyar**, Pharmacy Officer, Department of Drug Administration, MoHFS
- **Ms. Binala Joshi,** Pharmacy Officer, Department of Drug Administration, MoHFS
- **Mr. Umanga Tripathi**, Pharmacy Officer, Department of Drug Administration, MoHFS

We also gratefully acknowledge the technical support provided by the **World Health Organization (WHO) Nepal and Helen Keller International Nepal**, in particular:

- **Dr Gampo Dorji,** Senior Health Policy Advisor, HSP, WHO Nepal
- **Ms. Sushma Shakya**, Drug and Medical Product Officer, HSP, WHO Nepal
- **Dr. Sasmita Poudel,** Sr. Research Manager, Helen Keller International, Nepal

Their invaluable contributions in reviewing, providing technical input, and ensuring alignment with global standards have strengthened this revision of the NLEM.

Finally, we extend our appreciation to all stakeholders, directors and managers of various government entities and programs, various medical associations and societies, individual experts, and institutions whose active participation throughout the revision process and commitment to improving access to essential medicines in Nepal made this work possible.

TABLE OF CONTENT

Section A: Background.....1

Section B: NLEM 2026.....7

1. ANAESTHETICS, PERIOPERATIVE MEDICINES AND MEDICAL GASES.....9

2. MEDICINES FOR PAIN AND PALLIATIVE CARE.....10

3. ANTIALLERGICS AND MEDICINES USED IN ANAPHYLAXIS.....12

4. ANTIDOTES AND OTHER SUBSTANCES USED IN POISONINGS.....13

5. MEDICINES FOR NEUROLOGICAL DISORDERS 14

6. ANTI-INFECTIVE MEDICINES.....16

7. ANTIMIGRAINE MEDICINES 30

8. IMMUNOMODULATORS AND ANTINEOPLASTICS 31

9. THERAPEUTIC PRODUCTS TO TREAT MALNUTRITION DISORDERS.....34

10. MEDICINES AFFECTING THE BLOOD 37

11. BLOOD PRODUCTS, COAGULATION FACTORS, AND PLASMA SUBSTITUTES.....39

12. CARDIOVASCULAR MEDICINES.....40

13. DERMATOLOGICAL MEDICINES (TOPICAL) 43

14. DIAGNOSTIC AGENTS.....45

15. DISINFECTANTS AND ANTISEPTICS 46

16. DIURETICS.....47

17. GASTROINTESTINAL MEDICINES 48

18. MEDICINES FOR ENDOCRINE DISORDERS 50

19. IMMUNOLOGICALS 52

20. MUSCLE RELAXANTS (PERIPHERALLY ACTING) AND CHOLINESTERASE INHIBITORS) 54

21. OPHTHALMOLOGICAL PREPARATIONS 55

22. MEDICINES FOR REPRODUCTIVE HEALTH AND PERINATAL CARE 57

23. PERITONEAL DIALYSIS SOLUTION 60

24. MEDICINES FOR MENTAL AND BEHAVIOURAL DISORDER 61

25. MEDICINES ACTING ON THE RESPIRATORY TRACT 63

26. SOLUTION CORRECTING WATER, ELECTROLYTE AND ACID-BASE DISTURBANCES 64

27. VITAMINS AND MINERALS 65

28. EAR, NOSE AND THROAT MEDICINES 66

29. MEDICINES FOR DISEASES OF JOINTS 67

30. DENTAL MEDICINES AND PREPARATIONS 68

ANNEX I 69

ANNEX II 87

ANNEX III 88

ANNEX IV 91

ANNEX V 95

ANNEX VI 107

SECTION A: BACKGROUND

1. Context

Nepal initiated an essential medicine program in 1978, with the publication of the first National List of Essential Medicines (NLEM). Since then, it has been revised six times, with the latest update in 2021. The World Health Organization (WHO) updates its model List of Essential Medicines (EML) almost every two years that serves as a guide for countries, particularly Low- and Middle- income countries, to prepare and update their national essential medicines list. Revisions of the national list of essential medicines are critical to ensure they remain relevant to evolving public health challenges, incorporate new therapeutic options, and adapt to changing resistance patterns.

2. Methodology

The Department of Drug Administration (DDA) led the revision of NLEM 2026 with the formation of a Technical Working Group (TWG) composed of senior government officials and pharmacists. The TWG was supported by a three-member consultant team, including a public health expert, a clinical pharmacist, and a clinical pharmacologist engaged as part of the technical support from Helen Keller International, which also provided financial support for the revision process. Representatives from the Department of Health Services (DoHS), WHO Nepal team, and Helen Keller country office attended progress review and consultative meetings, as requested. The detailed methodology followed during the process of revision is outlined below:

2.1 Document Review

At the initial step, the WHO Model list of Essential Medicines, 2025 and National Essential Medicines Lists, National Treatment Guidelines, and Standard Treatment Protocols were reviewed and compared against the NLEM-2021 to identify potential molecules for inclusion and deletion. The availability of the proposed medicines for inclusion in the National Essential Medicines List (NEML) was verified using the Drug Administration Management System (DAMS), the official regulatory database maintained by the Department of Drug Administration (DDA). The details of the documents referred to during the preliminary screening of the potential molecules are mentioned below (non-exhaustive):

A. Global & National Essential Medicines Lists

- WHO Model list of Essential Medicines,24th Edition, 2025
- National list of Essential Medicines, 2021
- SAARC Region EMLs: India, Pakistan, Sri Lanka, Bhutan, Maldives and low- and middle-income countries EMLs: Kenya, Ethiopia, Uganda, Liberia

B. National Guidelines, Treatment Protocols and related documents

The guidelines and protocols reviewed during the gap analysis included but were not limited to the following:

- National TB Preventive Treatment Protocol 2024
- National Malaria Treatment Protocol 2019
- Clinical Handbook of TB management Protocol 2024
- National HIV testing and treatment guidelines 2022
- National Nutrition Policy and Strategy 2004
- National guidelines for the Integrated Management of Acute Malnutrition (IMAM) 2016
- Standard Treatment Protocol for Basic Health Services Package 2078
- Health Insurance Board Benefit Package 2081
- National Antimicrobial Treatment Guideline 2023

C. Supplementary Materials

- DDA New Drug Evaluation Forms / Formats
- Drug Administrative Management System (DAMS)

2.2 Gap Analysis

The results of the gap analysis were interpreted in following manner:

1. Government Program drugs, used in health programs but not included in NLEM Nepal (Potential molecule for addition)

2. NLEM Medicines Vs Health Insurance Board covered medicines (local relevance)-aimed to assess the local need for any medicine based on disease prevalence.

2.3 Stakeholder Mapping

Recognizing that a successful NLEM requires broad acceptance and diverse perspectives, mapping of the stakeholders and societies was done for extensive consultations (Annex 4).

- **Professional Societies and Associations:** Over 25 professional medical societies and associations were listed for necessary inputs.

- **Government Program managers:** Key divisions like Family Welfare Division, National Centre for AIDS and STD Control, National Tuberculosis Control Centre, and Logistic Management Section were enlisted to capture crucial programmatic insights required for aligning the proposed NLEM 2021 with program requirements.

- **Organizational Input:** World Health Organization Nepal and Helen Keller International provided valuable technical support and guidance throughout the revision process.

2.4 Development, and circulation of amendment request forms

Structured tools and formats were developed for capturing the amendment requests. DDA issued a written circular to all the selected stakeholders calling for their contributions in the revision of NLEM 2021 along with the formats for making amendment requests. All the stakeholders were continuously followed through telephone calls, and emails to ensure that the recommendations of any specialties are not missed out. In-person visits to experts related to different government health programs were also conducted by the consultant team. Likewise, the consultant team met with the subject matter experts from various specialties to gather additional insights. Different medical societies shared their feedback and made amendment requests through email, resulting in more than 300 amendment proposals.

2.5 Evaluation of amendment requests against evaluation criteria

The Drafting Committee developed criteria for both the Core/Main and Complementary lists, ensuring that selection is tailored to Nepal's specific needs while adhering to international best practices. The criteria developed are enumerated below:

Inclusion Criteria

Core (Main) List

1. Public Health Relevance: Addresses a major disease burden
2. Proven Efficacy & Safety: Based on clinical evidence, and inclusion in WHO Model list of essential medicines
3. Comparative Cost-Effectiveness: Superior to or more affordable than existing options
4. Availability: Registered with the DDA.
5. Alignment with local treatment protocols and clinical guidelines - health program priorities, coverage by the Health Insurance Board, and distributed by the government programs
6. Antimicrobial resistance concern
7. Alignment with the WHO Model Essential Medicines List 2025 and the National Essential Medicines List of selected Low- and Middle-Income countries and SAARC countries

Complementary List

1. Have higher costs, yet are justified due to therapeutic value
2. Are used as second-line options when alternatives are not effective

Similarly, criteria for deletion of a medicine from NLEM 2021 was also established as enumerated below:

1. Change in treatment algorithms
2. Reports of concerns on the safety profile of a medicine (pharmacovigilance data)

3. If better efficacy or favorable safety profile medicine or cost-effective medication is available.
4. Irrelevant to public health disease burden
5. Medicine with abuse and misuse potential

All the proposed amendment requests were evaluated against the above-mentioned criteria using the pre-established molecule evaluation template. The molecules were then suggested for addition/ deletion/ molecules that ought to be included in the NLEM were suggested for inclusion while the ones that have fallen into disuse for different reasons were suggested for deletion. In cases of drugs which were already listed in the NLEM 2021 but newer dosage forms or strengths were suggested and the need established were suggested for line extension, similarly some drug strengths which were no longer in use were suggested for line deletions. Some drugs were suggested for modifications in terms of added use case or changed use case based on their clinical use.

2.6 Development of NLEM-2026

A series of discussions and internal meetings were conducted between DDA TWG, Consultant team, and experts (Virtual/ In-person) throughout the process. After rigorous discussion, a preliminary list was put forward at the wider stakeholder meeting before finalization of NLEM 2026. Some of the milestones during the drafting of NLEM 2026 are enumerated in the table provided:

Table 1: Key milestones in the drafting of NLEM 2026

June 16th, 2025	Preliminary discussion on approach, timeline and structured tools/ instruments for consultation
June 29th, 2025	Finalization of different stakeholders list, preliminary discussion on gaps between NLEM 2021 and WHO Model List and EMLs of selected countries
July 21st, 2025	Discussion on evaluation of information from different societies, experts and partners
July 30th, 2025	Pre-stakeholder consultation meeting

August 4th, 2025	Consultative Workshop/ Meeting
August 13th, 2025	Final discussion on incorporation of the feedbacks received

SECTION B: NLEM 2026

1. Summary of major changes reflected in NLEM 2026

1. Adoption of WHO style of formatting

- Introduction of new sections and sub-sections and changes to names

  Section 2.3: Medicines for other common symptoms in palliative care

  Section 5. Medicines for neurological disorders (changed from Anticonvulsants/ Antiepileptics)

  Section 5.1 Medicines for central nervous system disorders

  Section 5.1.1 Antiseizure medicines

  Section 5.1.2 Medicines for multiple sclerosis

  Section 5.1.3 Medicines for Parkinsonism (Shifted from section 9)

  Section 5.1.4 Medicines for cerebral palsy

  Section 5.2 Medicines for peripheral nervous system disorders

  Section 5.2.1 Medicines for myasthenia gravis

  Section 8. Immunomodulators and Antineoplastics (previously titled: Immunomodulators, Antineoplastic, and Medicines used in palliative care)

  Section 9. Therapeutic products to treat malnutrition disorders (Previously: Medicines for Parkinsonism)

  Section 13.6 Humectants

  Section 22.4 Medicines for medical abortion (New section formed, earlier under 22.3 Uterotonics)

  30: Dental medicines and preparations (Shifted from section 28)

2. NLEM-2026 includes 436 medicines. 139 total changes with 52 additions, 32 line extensions, 14 deletions, 8 line deletions, 33 modifications.

3. **Additions**
   52 new medicines (highest in immunomodulators and anti-neoplastics- 9 additions, anti-infective medicines - 5 additions)

4. **Line extension**
   32-line extensions, highest line extension in 5 in anti-infectives, 5 in immunomodulators and anti-infectives, 4 in medicines for mental and behavioural disorder.

5. **Deletions**
   14 molecules delisted, 8 deletions in anti-infective medicines.

6. **Line deletions**
   Total 8-line deletions, four in anti-infectives and three in cardiovascular medicines.

7. **Modifications**
   33 in total, major modifications on section 2.3-medicines for other common symptoms in palliative care (10), and section 30-dental medicines and preparations (4)

2. Additional documents included

1. The NLEM-2026
2. Annex-1 Drug Addition/Deletion
3. Annex-2 Medicines with age or weight restrictions
4. Annex-3 Explanation of dosage forms
5. Annex-4 List of stakeholders/ experts consulted
6. Annex 5 List of amendment requests
7. Annex-6 List of medicines in NLEM 2026 (index)
8. Slide deck (Molecules evaluation)

1 ANAESTHETICS, PERIOPERATIVE MEDICINES AND MEDICAL GASES

1.1	**General anaesthetics and oxygen**	
1.1.1	**Inhalational medicines**	
	isoflurane	Inhalation
	nitrous oxide*	inhalation *Piped nitrous oxide is a major source of atmospheric pollution from healthcare facilities. Point-of-care cylinders are the preferred delivery system over centrally-supplied (piped) delivery systems.
	oxygen	Inhalation (medical gas)
	sevoflurane	Inhalation
1.1.2	**Injectable medicines**	
	ketamine	Injection: 50 mg/ml (as hydrochloride) in 10 ml vial
	propofol	Injection: 10 mg/ml in 20 ml ampoule
1.2	**Local anaesthetics**	
	bupivacaine	Injection: 0.25%, 0.5% (hydrochloride) in vial Injection for spinal anesthesia: bupivacaine 5 mg (hydrochloride)/ ml (0.5%) in 4 ml ampoule to be mixed with 8% glucose solution
	lidocaine (lignocaine)	Injection: 0.5% [c]; 1%, 2% (hydrochloride) in vial Injection for spinal anaesthesia: 5% (as hydrochloride) in 2 ml ampoule to be mixed with 7.5% glucose solution Topical (sterile): 2% w/w
	lidocaine (lignocaine) + epinephrine (adrenaline)	Injection: 2% (as hydrochloride or sulfate) + epinephrine 1: 200 000 in vial
1.3	**Preoperative medication and sedation for short-term procedures**	
	atropine	Injection: 400 micrograms/mL [c]; 0.6 mg (as sulfate)/ ml in 1 ml ampoule, 30 ml vial
	diazepam	Injection: 5 mg/ ml in 2 ml ampoule
	glycopyrrolate	Injection: 0.2 mg/ ml in ampoule
	midazolam	Injection: 1 mg/ ml, 5 mg/ ml
	morphine	Injection: 1 mg/mL [c]; 2 mg/mL[c]; 10 mg (sulfate or hydrochloride) in 1 ml ampoule Oral liquid: 10 mg (sulfate or hydrochloride)/ 5 ml

2 MEDICINES FOR PAIN AND PALLIATIVE CARE

2.1	**Non-opioid analgesics and non-steroidal anti-inflammatory medicines (NSAIMs)**	
	ibuprofen [c] [a]	Oral liquid: 200 mg/ 5 ml Tablet: 200 mg, 400 mg [a] not in children less than 3 months (except IV form for patent ductus arteriosus)
	paracetamol *	Injection: 150 mg/ ml in 2 ml ampoule, 10 mg/ ml in 100 ml bottle Oral liquid: 125 mg/ 5 ml [c] as suspension, 150 mg/ml as drops Suppository: 125 mg, 250 mg Tablet: 500mg * Not recommended for anti-inflammatory use due to lack of proven benefit to that effect.
	Complementary list	
	Acetylsalicylic acid (aspirin)	Tablet: 500 mg
	Diclofenac sodium	Injection:75 mg/ ml Tablet: 50 mg, 100 mg
2.2	**Opioid analgesics**	
	codeine	Tablet: 30 mg (phosphate)
	fentanyl *	Injection: 50 mcg/ ml * For the management of cancer pain, intraoperative and post-operative pain management.
	morphine	Injection: 1 mg/mL [c]; 2 mg/mL[c]; 10 mg (morphine sulfate or morphine hydrochloride) in 1 ml ampoule Oral liquid: 10 mg (hydrochloride or sulfate)/ 5 ml Tablet (immediate release): 10 mg (sulfate) Tablet (prolonged release): 10 mg, 30 mg, 60 mg (hydrochloride or sulfate)
	pethidine	Injection: 50 mg (hydrochloride) in 1 ml ampoule
2.3	**Medicines for other common symptoms in palliative care**	
	amitriptyline	Tablet: 10 mg, 25 mg, 75 mg

Dexamethasone	Injection: 4 mg (as disodium phosphate salt)/ml in 1 ml ampoule Tablet: 500 mcg, 4 mg
diazepam	Injection: 5 mg/ml in 2 ml ampoule Tablet (scored): 5 mg; 10 mg
fluoxetine [a]	Solid oral dosage form:20 mg (as hydrochloride) [a] > 8 years
haloperidol	Injection: 5 mg/ ml in 1 ml ampoule Tablet: 0.5 mg, 2 mg, 5 mg
hyoscine butylbromide	Injection: 20 mg/ ml in 1 ml ampoule Tablet: 10 mg, 20 mg
lactulose	Solution: 3.35 g / 5 ml
loperamide [a]	Solid oral dosage form: 2 mg [a] > 2 years
metoclopramide [a]	Injection: 5 mg (hydrochloride)/ ml in 2 ml ampoule Tablet: 10 mg (hydrochloride) [a] not in neonates
midazolam	Injection: 1 mg/ ml, 5 mg/ ml
ondansetron [a]	Injection: 2 mg (as hydrochloride)/ ml in 2 ml, 4 ml vial Oral liquid: 4 mg base/5 ml Tablet: 2 mg, 4 mg (as hydrochloride) [a] not in infants ≤ 1 month

3 ANTIALLERGICS AND MEDICINES USED IN ANAPHYLAXIS

dexamethasone	Injection: 4 mg (as disodium phosphate salt)/ ml in 1 ml ampoule Oral liquid: 2 mg/5 mL (as sodium phosphate). Tablet: 2 mg; 4 mg (as dexamethasone base) *hydrocortisone preferred in neonates
epinephrine (adrenaline)	Injection: 1 mg (as hydrochloride or hydrogen tartrate) in 1 ml ampoule (1:1000)
hydrocortisone	Powder for injection: 100 mg (as sodium succinate) in vial with water for injection
levocetirizine	Tablet: 5 mg
pheniramine	Injection: 22.75 mg (maleate)/ ml Tablet: 25mg, 50 mg
prednisolone	Tablet: 5mg, 10 mg, 20 mg
Complementary list	
fexofenadine	Oral solution: 30mg/ 5 ml

4 ANTIDOTES AND OTHER SUBSTANCES USED IN POISONINGS

4.1	**Non-specific**	
	Charcoal, activated	Powder: 10 g in sachet (oral liquid as sorbitol-base slurry)
4.2	**Specific**	
	acetylcysteine	Injection: 200 mg/ ml in 10 ml ampoule Tablet (effervescent): 600 mg
	atropine [a]	Injection: 0.6 mg/ ml in 1 ml ampoule, 30 ml vial [a] >3 months
	calcium gluconate	Injection: 100 mg/ ml in 10 ml ampoule
	methylthioninium chloride (methylene blue)	Injection: 10 mg/ ml in 10 ml ampoule
	naloxone	Injection: 400 mcg (hydrochloride) in 1 ml ampoule
	potassium ferric hexacyanoferrate (Prussian blue)	Powder: For oral administration
	pralidoxime	Injection: 500 mg , 1 g (mesilate, chloride or iodide) in ampoule
	protamine sulfate [c]	Injection: 10 mg/ ml in 5 ml ampoule
	sodium nitrite	Injection: 30 mg/ ml in 10 ml ampoule
	Complementary list	
	deferoxamine	Powder for injection: 500 mg (mesilate) in vial
	dimercaprol	Injection in oil: 50 mg/ ml in 2 ml ampoule
	fomepizole	Injection: 5 mg (sulfate)/ ml in 20 ml ampoule
	sodium calcium edetate	Injection: 200 mg/ ml in 5 ml ampoule
	succimer	Solid oral dosage form: 100 mg

5 MEDICINES FOR NEUROLOGICAL DISORDERS

5.1	**Medicines for central nervous s ystem disorders**	
5.1.1	**Antiseizure medicines**	
	carbamazepine	Oral liquid: 100 mg/ 5 ml Tablet: 100 mg, 200 mg, 400 mg
	diazepam	Injection: 5mg/ ml in 2 ml ampoule (intravenous or rectal)
	magnesium sulfate *	Injection: 500 mg/ ml in 2 ml ampoule, in 10 ml ampoule * For use in eclampsia and severe pre-eclampsia and not for other convulsant disorders
	lamotrigine*	Tablet: 25 mg, 50 mg,100 mg,200 mg *For use as adjunctive therapy for treatment-resistant partial or generalized seizures.
	levetiracetam	Oral solution: 100 mg/ml Tablet: 250 mg, 500 mg
	phenobarbital	Injection: 200mg (sodium)/ ml Oral liquid: 15 mg/5 ml Tablet: 15 mg, 30 mg, 60 mg
	phenytoin	Injection: 50 mg (sodium salt)/ ml in 5 ml vial Oral liquid: 30 mg/5 ml Solid oral dosage form: 25 mg, 50 mg, 100 mg (sodium salt)
	prednisolone	Oral liquid: 1mg/ml Tablet: 1mg, 5mg, 10 mg
	valproic acid *	Oral liquid: 200 mg/5 ml Tablet (enteric coated): 200 mg, 500 mg (sodium salt) *Avoid use in pregnancy and in women and girls of child-bearing potential, unless alternative treatments are ineffective or not tolerated because of the high risk of birth defects and developmental disorders in children exposed to valproate in the womb.
	Complementary list	
	valproic acid *	Injection: 100 mg/ ml *Avoid use in pregnancy and in women and girls of child-bearing potential, unless alternative treatments are ineffective or not

		tolerated because of the high risk of birth defects and developmental disorders in children exposed to valproate in the womb.
5.1.2	**Medicines for multiple sclerosis**	
	Complementary list	
	rituximab	Injection (intravenous): 10 mg/ml
5.1.3	**Medicines for Parkinsonism**	
	levodopa + carbidopa	Tablet: 100 mg + 10 mg, 250 mg + 25 mg
	trihexyphenidyl (benzhexol)	Tablet: 2 mg (hydrochloride)
5.1.4	**Medicines for cerebral palsy**	
	Complementary list	
	baclofen	Tablet: 10 mg
5.2	**Medicines for peripheral nervous system disorders**	
5.2.1	**Medicines for myasthenia gravis**	
	neostigmine	Injection: 500 micrograms in 1 ml ampoule; 2.5 mg (metilsulfate) in 1 ml ampoule Tablet: 15 mg (bromide)
	Complementary list	
	pyridostigmine	Tablet 60: mg, 180 mg SR Tablets

6 ANTI-INFECTIVE MEDICINES

6.1	**Anthelminthics**	
6.1.1	**Intestinal anthelminthics**	
	albendazole	Tablet: (chewable) 400 mg Oral liquid: 400 mg/ 10 ml
	ivermectin	Tablet: 3 mg
	mebendazole	Tablet: 100 mg
	niclosamide	Tablet: (chewable) 500 mg
	praziquantel	Tablet: 150 mg, 600 mg
6.1.2	**Antifilarials**	
	albendazole	Tablet: (chewable) 400 mg
	diethylcarbamazine	Tablet: 50 mg, 100 mg (dihydrogen citrate)
	ivermectin	Tablet: 3 mg

6.2 Antibacterials

To assist in the development of tools for antibiotic stewardship at primary, secondary, and tertiary level hospitals to reduce antimicrobial resistance, the Access, Watch, Reserve (aWaRe) classification of antibiotics was developed- where antibiotics are classified into different groups to emphasize the importance of their appropriate use.

ACCESS GROUP ANTIBIOTIC

This group includes antibiotics that have activity against a wide range of commonly encountered susceptible pathogens while also showing lower resistance potential than antibiotics in the other group. Selected Access group antibiotics are recommended as essential first or second choice empiric treatment options for infectious syndromes as reviewed by the WHO EML Expert Committee. They are listed as individual medicines in the National List of Essential Medicines to improve access and promote appropriate use. They are essential antibiotics that should be widely available, affordable and quality assured.

WATCH GROUP ANTIBIOTICS

This group includes antibiotic classes that have higher resistance potential and includes most of the highest priority agents among the Critically Important Antimicrobials for Human Medicine and/ or antibiotics that are at relatively high risk of selection of bacterial resistance. These medicines should be prioritized as

key targets of stewardship programs and monitoring. Selected Watch group antibiotics are recommended as essential first or second choice empiric treatment options for a limited number of specific infectious syndromes as reviewed by the WHO EML Expert Committee.

RESERVE GROUP ANTIBIOTICS

This group includes antibiotics and antibiotic classes that should be reserved for treatment of confirmed or suspected infections due to multi-drug-resistant organisms. Reserve group antibiotics should be treated as "last resort" options. Selected Reserve group antibiotics are listed as individual medicines in the National List of Essential Medicines when they have a favourable risk-benefit profile and proven activity against "Critical Priority" or "High Priority" pathogens identified by the WHO Priority Pathogens List. These antibiotics should be accessible, but their use should be tailored to highly specific patients and settings, when all alternatives have failed or are not suitable. These medicines could be protected and prioritized as key targets of stewardship programs involving monitoring and utilization reporting, to preserve their effectiveness.

Disclaimer: The empiric treatment options for infectious syndromes for access group and watch group are adapted from WHO EML model list 23rd edition. The empiric treatment may be modified according to the local sensitivity pattern or hospital cumulative Antibiotic Sensitivity Test.

Bibliography:

WHO Model List of Essential Medicines – 24th list, 2025
https://iris.who.int/server/api/core/bitstreams/17642505-ecd3-4940-a691-4f1dfa0d835a/content

6.2.1	**Access group antibiotics**		
	amoxicillin	Powder for injection: 250 mg, 500 mg, 1 g (as sodium) in vial Powder for oral liquid:125 mg (as trihydrate)/ 5 ml [c] Solid oral dosage form: 250 mg, 500 mg (as trihydrate) Tablet (dispersible): 125 mg, 250 mg [c] (as trihydrate)	
		FIRST CHOICE *- community acquired pneumonia (mild to*	SECOND CHOICE *- acute bacterial meningitis*

	moderate) *- community acquired pneumonia (severe) [c]* *- complicated severe acute malnutrition [c]* *- exacerbations of COPD* *- lower urinary tract infections* *- otitis media* *- pharyngitis* *- sepsis in neonates and children [c]* *- sinusitis* *- uncomplicated severe acute malnutrition [c]* *- progressive apical dental abscess*	
amoxicillin + clavulanic acid	Powder for injection: 500 mg (as sodium) + 100 mg (as potassium salt); 1000 mg (as sodium) + 200 mg (as potassium salt) in vial Tablet: 500 mg (as trihydrate) + 125 (as potassium salt) mg, 875 mg (as trihydrate) + 125 (as potassium salt) mg	
	FIRST CHOICE *- community acquired pneumonia (severe) [c]* *- complicated intraabdominal infections (mild to moderate)* *- exacerbations of COPD - hospital acquired pneumonia* *- low-risk febrile neutropenia* *- lower urinary tract infections* *- sinusitis - skin and soft tissue infections*	SECOND CHOICE *- bone and joint infections* *- community-acquired pneumonia (mild to moderate)* *- community acquired pneumonia (severe)* *- otitis media* *- surgical prophylaxis*
ampicillin	Powder for injection: 500 mg (as sodium salt) in vial Capsule: 500 mg	
	FIRST CHOICE *- community-acquired pneumonia (severe) [c]* *- complicated severe acute malnutrition [c]*	SECOND CHOICE *- acute bacterial meningitis*

	- sepsis in neonates and children [c]	
benzathine benzylpenicillin	Powder for injection: 60 000 IU, 1200 000 IU [c], 2400 000 IU in vial	
	FIRST CHOICE *- syphilis*	SECOND CHOICE
benzylpenicillin (penicillin G)	Powder for injection: 300 mg (= 0.5 million IU), 600 mg (=1 million IU) (as sodium or potassium salt) in vial	
	FIRST CHOICE *- community acquired pneumonia (severe) [c]* *- complicated severe acute malnutrition [c]* *- sepsis in neonates and children* [c] *- syphilis*	SECOND CHOICE *- acute bacterial meningitis*[c]
cephalexin	Capsule: 250 mg (as monohydrate) Oral Powder for reconstitution with water: 125 mg/ 5 ml, 250 mg/ 5 ml (anhydrous)	
	FIRST CHOICE	SECOND CHOICE *- exacerbations of COPD* *- pharyngitis* *- skin and soft tissue infections*
chloramphenicol	Capsule:250 mg, 500 mg Powder for injection: 1g (as sodium succinate) in vial Oral liquid: 125 mg (as palmitate)/ 5 ml	
	FIRST CHOICE	SECOND CHOICE *- acute bacterial meningitis*
cloxacillin	Capsule: 250 mg [c], 500 mg (as sodium salt) Powder for injection: 500 mg (as sodium salt) in vial Powder for oral liquid:125 mg (as sodium salt)/ 5 ml (as sodium) [c]	
	FIRST CHOICE *- bone and joint infections* *- skin and soft tissue infections*	SECOND CHOICE *- sepsis in neonates and children [c]*
doxycycline [a]	Capsule:100 mg (as hydrochloride) Oral liquid:25 mg/ 5 ml [c], 50 mg/ 5 ml [c](anhydrous) Powder for injection: 100 mg in vial	

	Solid oral dosage form:50 mg [c], 100 mg (hyclate) [a] Use in children <8 years only for life-threatening infections when no alternative exists	
	FIRST CHOICE *- sexually transmitted infection due to Chlamydia trachomatis* *- cholera* *-scrub typhus*	SECOND CHOICE *- cholera [c]* *- community-acquired pneumonia (mild to moderate)* *- exacerbations of COPD*
gentamicin	Injection:10 mg, 40 mg (as sulfate)/ ml in 2 ml vial	
	FIRST CHOICE *- community acquired pneumonia (severe) [c]* *- complicated severe acute malnutrition [c]* *- sepsis in neonates and children [c]*	SECOND CHOICE *- gonorrhoea* *- surgical prophylaxis*
metronidazole	Injection: 500 mg in 100 ml vial Oral liquid:100 mg/ 5 ml, 200 mg (as benzoate)/ 5 ml Tablet: 200 mg, 400 mg	
	FIRST CHOICE *- C. difficile infection* *-complicated intraabdominal infections (mild to moderate)* *- complicated intra-abdominal infections (severe)* *- trichomoniasis* *- surgical prophylaxis*	SECOND CHOICE *-complicated intraabdominal infections (mild to moderate)*
nitrofurantoin	Oral liquid: 25 mg/ 5 ml [c] Tablet: 50mg [c], 100 mg	
	FIRST CHOICE *- lower urinary tract infections*	SECOND CHOICE
phenoxymethyl penicillin (penicillin V)	Powder for oral liquid: 250 mg (as potassium salt)/ 5 ml Tablet: 250 mg (as potassium salt)	
	FIRST CHOICE *- community acquired pneumonia (mild to moderate)*	SECOND CHOICE

		- pharyngitis *-progressive apical dental abscess*	
	procaine benzylpenicillin *	Powder for injection: 300 000 IU in vial * Procaine benzylpenicillin is not recommended as first line treatment for neonatal sepsis except in a setting with high neonatal mortality, when given by trained health workers in cases where hospital care is not achievable	
		FIRST CHOICE *- syphilis [c]*	SECOND CHOICE *- syphilis*
	sulfamethoxazole + trimethoprim *	Injection: 80 mg + 16 mg / ml in 5 ml ampoule 80 mg +16 mg/ ml in 10 ml ampoule Oral liquid:200 mg + 40 mg /5 ml Tablet (dispersible): 100 mg + 20 mg [c], 400 mg +80 mg, 800 mg + 160 mg * Single agent trimethoprim may be an alternative for lower urinary tract infection	
		FIRST CHOICE *- lower urinary tract infections*	SECOND CHOICE *-acute invasive diarrhoea/ bacterial dysentery*
	Complementary list		
	cefazolin [a]	Powder for injection: 1g (as sodium salt) in vial [a] > 1 month	
		FIRST CHOICE *- surgical prophylaxis*	SECOND CHOICE *- bone and joint infections*
6.2.2	**Watch group antibiotics**		
	amikacin	Injection: 250 mg (as sulfate)/ ml in 2 ml vial	
		FIRST CHOICE *-pyelonephritis or prostatitis (severe)* *- high-risk febrile neutropenia*	SECOND CHOICE *- sepsis in neonates and children [c]*
	azithromycin	Oral liquid: 200 mg/ 5 ml Solid oral dosage form: 250 mg, 500 mg (anhydrous)	
		FIRST CHOICE *- sexually transmitted infection due to Chlamydia trachomatis*	SECOND CHOICE *- acute invasive bacterial diarrhoea / dysentery* *- gonorrhoea* *-scrub typhus*

	- cholera [c] *- gonorrhoea*	
cefixime	Powder for oral liquid: 100 mg/ 5 ml [c] Solid oral dosage form: 200 mg, 400 mg (as trihydrate)	
	FIRST CHOICE	SECOND CHOICE *- acute invasive bacterial diarrhoea / dysentery* *- gonorrhoea*
ceftazidime	Powder for injection: 250 mg, 500mg, 1 g (as pentahydrate) in vial	
	FIRST CHOICE *– Endophthalmitis*	SECOND CHOICE *-Infective Exacerbation of COPD*
ciprofloxacin	Oral liquid: 250 mg / 5 ml (anhydrous) [c] Solution for IV infusion: 2 mg/mL (as hyclate) [c] Tablet: 250 mg, 500 mg (as hydrochloride)	
	FIRST CHOICE *- acute invasive bacterial diarrhoea / dysentery* *- low-risk febrile neutropenia* *- pyelonephritis or prostatitis (mild to moderate)* *- enteric fever*	SECOND CHOICE *- cholera* *- complicated intraabdominal infections (mild to moderate)*
clindamycin	Capsule: 150mg (as hydrochloride) Injection: 150 mg (as phosphate)/ ml Oral liquid: 75 mg (as palmitate)/5 ml [c]	
	FIRST CHOICE	SECOND CHOICE *- bone and joint infections*
erythromycin	Oral liquid: 250 mg (as stearate)/ 5 ml Tablet: 250 mg (as stearate)	
	FIRST CHOICE *- community acquired pneumonia (severe)*	SECOND CHOICE *- pharyngitis*
Complementary list		
cefotaxime *	Powder for injection: 250 mg, 500 mg, 1g (as sodium salt) per vial * 3rd generation cephalosporin of choice for use in hospitalized neonates	

<table>
<tr><td></td><td>FIRST CHOICE
- acute bacterial meningitis
- community acquired pneumonia (severe)
- complicated intraabdominal infections (mild to moderate)
- complicated intrabdominal infections(severe)
- hospital-acquired pneumonia
- pyelonephritis or prostatitis (severe)</td><td>SECOND CHOICE
- bone and joint infections
- pyelonephritis or prostatitis (mild to moderate)
- sepsis in neonates and children [c]</td></tr>
<tr><td rowspan="2">ceftriaxone* [a]</td><td colspan="2">Powder for injection: 250 mg, 1 g (as sodium salt) in vial
* Do not administer with calcium and avoid in infants with hyperbilirubinemia
[a] use in infants >41 weeks corrected gestational weeks</td></tr>
<tr><td>FIRST CHOICE
- acute bacterial meningitis
- community acquired pneumonia (severe)
- complicated intraabdominal infections (mild to moderate)
- complicated intrabdominal infections(severe)
- hospital acquired pneumonia
- gonorrhoea
- pyelonephritis or prostatitis (severe)
- enteric fever</td><td>SECOND CHOICE
- acute invasive bacterial diarrhoea/ dysentery
- bone and joint infections
- pyelonephritis or prostatitis (mild to moderate)
- sepsis in neonates and children [c]</td></tr>
<tr><td rowspan="2">ciprofloxacin *</td><td colspan="2">Solution for IV infusion: 2 mg/ ml [c] in 100 bottle
* For adults only</td></tr>
<tr><td>FIRST CHOICE
- acute invasive bacterial diarrhea / dysentery
- low-risk febrile neutropenia
- pyelonephritis or prostatitis</td><td>SECOND CHOICE
- cholera
- complicated intraabdominal infections (mild to moderate)</td></tr>
</table>

		(mild to moderate) *- enteric fever*	
	clarithromycin†	Powder for oral liquid: 125 mg/5 ml; 250 mg/5 ml Powder for injection: 500 mg in vial Solid oral dosage form: 500 mg †clarithromycin is also listed for use in combination regimens for eradication of H. pylori in adults	
		FIRST CHOICE *-community acquired pneumonia (severe)*	SECOND CHOICE *- pharyngitis*
6.2.3	**Reserve group antibiotics**		
	meropenem	Powder for injection: 500mg, 1 g (as trihydrate) in vial a > 3 months.	
	polymyxin B	Powder for injection: 500,000 IU in vial	
	piperacillin + tazobactam	Powder for injection: 2g (as sodium salt) + 250 mg (as sodium salt); 4 g (as sodium salt) + 500 mg (as sodium salt) in vial	
	vancomycin	Powder for injection: 250 mg (as hydrochloride) in vial	
	Complementary list		
	colistin	Powder for injection: 1 million I.U. (as colistemethate sodium) in vial	
	fosfomycin	Powder for injection: 2 g; 4 g (as sodium) in vial; Solid oral dosage form: 3g	
	linezolid	Injection for intravenous administration: 2 mg/ml in 300 ml bag Powder for oral liquid: 100 mg/5 ml Tablet: 400 mg, 600 mg	
6.2.4	**Antileprosy medicines**		
	Combination therapy is essential to prevent the emergence of drug resistance.		
	clofazimine	Capsule:50 mg, 100 mg	
	dapsone	Tablet: 50 mg, 100 mg	
	rifampicin*	Solid oral dosage form:150 mg, 300 mg * Used for Leprosy Post-Exposure prophylaxis.	
6.2.5	**Antituberculosis medicines**		
	ethambutol	Tablet:100 mg, 400 mg, 600 mg (hydrochloride) Tablet (dispersible): 100 mg [c]	
	ethambutol + isoniazid +	Tablet: 275 mg + 75 mg + 400 mg + 150mg	

	pyrazinamide + rifampicin	
	ethambutol + isoniazid + rifampicin	Tablet: 275 mg + 75 mg + 150 mg
	isoniazid	Tablet: 50 mg, 100 mg, 300 mg
	isoniazid + pyrazinamide +rifampicin	Tablet: 75 mg + 400 mg+ 150 mg Tablet (dispersible): 50 mg + 150 mg+ 75mg [c]
	isoniazid + rifampicin	Tablet: 75 mg + 150 mg, 150 mg + 300 mg Tablet (dispersible): 50 mg + 75 mg [c]
	pyrazinamide	Tablet: 150 mg, 400 mg, 500 mg Tablet (dispersible): 150 mg
	rifabutin	Tablet: 150 mg
	rifampicin	Capsule or Tablet: 150 mg, 300 mg, 450 mg
	Complementary list	
	Medicines for the treatment of multidrug-resistant tuberculosis (MDR-TB) should be used in specialized centers adhering to standard treatment protocol	
	amoxicillin + clavulanic acid *	Tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt), 875 mg (as trihydrate) + 125 mg (as potassium salt) * For use only in combination with meropenem
	bedaquiline	Tablet: 100 mg
	clofazimine	Capsule: 100 mg
	cycloserine	Capsule: 250 mg
	delamanid	Tablet: 50 mg
	ethionamide	Tablet: 125 mg, 250 mg
	levofloxacin	Tablet: 250 mg, 500 mg,750 mg Tablet (dispersible): 100 mg [c]
	linezolid	Tablet: 300 mg, 600 mg
	meropenem	Powder for injection: 500 mg, 1 g (as trihydrate) in vial
	moxifloxacin	Tablet: 400 mg
	p-aminosalicylic acid	Oral granules: 4 g, 9.2 g in sachet Tablet: 500 mg
	pretomanid	Tablet: 200 mg
	rifapentine*	Tablet: 150/300 mg Tablet (dispersible, scored): 150 mg [c] *Used for the TB Preventive treatment in combination with Isoniazid (3HP/1HP regimen).
6.3	**Antifungal medicines**	

	amphotericin B	Powder for injection: 50 mg in vial (as deoxycholate or liposomal complex)
	clotrimazole	Cream: 1% w/w Vaginal tablet (pessary): 100 mg Mouth paint: 1 % w/v
	fluconazole	Solid oral dosage form: 150 mg , 200 mg
	flucytosine	Capsule: 500 mg
	itraconazole	Capsule: 100 mg Oral liquid: 10 mg/ml * For treatment of chronic pulmonary aspergillosis, histoplasmosis, sporotrichosis, paracoccidiodomycosis, mycoses caused by T. marneffei and chromoblastomycosis; and prophylaxis of histoplasmosis and infections caused by T. marneffei in AIDS patients.
	nystatin	Oral liquid:50 mg/ 5 ml [c], mouth paint: 100 000 IU/ ml [c]
6.4	**Antiviral medicines**	
6.4.1	**Antiherpes medicines**	
	Complementary list	
	aciclovir	Powder for Injection:250 mg (as sodium salt) in vial Tablet: 200 mg, 400 mg, 800 mg
6.4.2	**Antiretroviral**	
6.4.2.1	***Nucleoside/Nucleotide reverse transcriptase inhibitors***	
	abacavir (ABC)	Tablet:300 (as sulfate)
	lamivudine (3TC)	Oral liquid: 50 mg/ 5 ml [c] Tablet: 150 mg
	tenofovir disoproxil fumarate * (TDF)	Tablet: 300 mg (equivalent to 245 mg tenofovir disoproxil) * Also indicated for pre-exposure prophylaxis
	zidovudine (ZDV or AZT)	Oral liquid: 50 mg/ 5 ml Tablet: 300 mg
6.4.2.2	***Non-nucleoside reverse transcriptase inhibitors***	
	nevirapine (NVP) [a]	Dispersible Tablet: 50 mg Oral liquid: 50 mg/ 5 ml, 10 mg/ ml [a] > 6 weeks
6.4.2.3	***Protease inhibitors***	
	atazanavir + ritonavir [a]	Tablet (heat stable): 300 mg (as sulfate) + 100 mg [a] ≥3 months and weighing ≥5 kg
	darunavir [a]	Tablet: 75 mg, 400 mg, 600 mg, 800 mg [a] > 3 years of age
	lopinavir + ritonavir (LPV/r)	Solid oral dosage form: 40mg + 10 mg [c]; Tablet (heat stable): 100 mg + 25 mg, 200mg+

		50 mg
	ritonavir	Tablet (heat stable): 25 mg, 100 mg [c]
6.4.2.4	***Integrase inhibitor***	
	dolutegravir [a]	Tablet (Dispersible, scored): 10 mg [c] ≥ 4 weeks and ≥ 3 kg (10 mg dispersible Tablet) Tablet: 50 mg ≥ 25 kg (50 mg dispersible tablet)
	raltegravir *	Tablet: 400 mg, 100 mg granules for suspension *For use in pregnant women and in second-line regimens in accordance with WHO treatment guidelines
6.4.2.5	***Fixed-dose combinations***	
	abacavir + lamivudine	Tablet (dispersible, scored): 120 mg (as sulfate) + 60 mg
	dolutegravir + lamivudine + tenofovir	Tablet: 50 mg + 300 mg + 300 mg (disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)
	emtricitabine₸ + tenofovir *	Tablet: 200mg + 300 mg (disoproxil fumarate equivalent to 245 mg tenofovir disoproxil) * Combination also indicated for pre-exposure prophylaxis
	lamivudine + tenofovir	Tablet: 300 mg + 300 mg
	lamivudine + zidovudine	Tablet: 30 mg + 60 mg [c], 150 mg +300 mg
6.4.3	**Other antivirals**	
	oseltamivir *	Capsule: 30 mg,45 mg, 75 mg (as phosphate) Oral powder: 6 mg/ ml (as phosphate) [c] * Severe illness due to confirmed or suspected influenza virus infection in critically ill hospitalized patients
	Complementary list	
	ganciclovir	Powder for injection: 500 mg in vial
	Valganciclovir [c] *	Tablet: 450 mg * For the treatment of cytomegalovirus retinitis (CMVr)
6.4.4	**Antihepatitis medicines**	
6.4.4.1	***Medicines for hepatitis B***	
6.4.4.1.1	**Nucleoside/Nucleotide reverse transcriptase inhibitors**	
	entecavir	Oral liquid: 0.05 mg/ ml Tablet: 0.5 mg; 1 mg
	tenofovir disoproxil fumarate (TDF)	Tablet: 300 mg (tenofovir disoproxil fumarate – equivalent to 245 mg tenofovir disoproxil)

	tenofovir alafenamide	Tablet: 25 mg
6.4.4.2	***Medicines for hepatitis C***	
	WHO guidelines recommend the use of pangenotypic direct-acting antiviral (DAA) regimens for the treatment of all adults, adolescents and children with chronic HCV infection aged 3 years and above, regardless of stage of disease.	
6.4.4.2.1	**Pangenotypic direct-acting antiviral combinations**	
	daclatasvir + sofosbuvir	Tablet: 400mg + 60 mg
	sofosbuvir	Granules: 200 mg in sachet [c]. Tablet: 200 mg; 400 mg
	sofosbuvir + velpatasvir	Tablet: 400 mg + 100 mg; 200 mg + 50 mg
6.4.4.2.2	**Non-pangenotypic direct-acting antiviral combinations**	
	ledipasvir + sofosbuvir	Tablet: 90 mg + 400 mg
6.4.4.2.3	**Other antivirals for hepatitis C**	
	ribavirin	Injection for intravenous administration: 800 mg and 1 g in 10ml phosphate buffer solution. Solid oral dosage form: 200 mg, 400 mg * For the treatment of hepatitis C, in combination with direct acting anti-viral medicines
6.5	**Antiprotozoal medicines**	
6.5.1	**Antiamoebic and antigiardiasis medicines**	
	metronidazole	Oral liquid: 200 mg (as benzoate)/ 5 ml Tablet: 200 mg, 400 mg
	Complementary list	
	secnidazole	Oral granules: 2 gm * For single dose in the treatment of amoebiasis
	tinidazole*	Tablet: 500 mg
6.5.2	**Antileishmaniasis medicines**	
	amphotericin B	Powder for Injection: 50 mg in vial (as sodium deoxycholate or liposomal complex)
	miltefosine	Capsule: 50 mg
	paromomycin	Injection: 375 mg (base as sulfate)/ ml in 2 ml ampoule
6.5.3	**Antimalarial medicines**	
6.5.3.1	***For curative treatment***	
	artemether + lumefantrine [a]	Tablet: 20 mg + 120 mg [a] Not recommended in the first trimester of pregnancy or in children below 5 kg weight

	chloroquine *	Oral liquid:50 mg (as phosphate or sulfate)/ 5 ml Tablet:150 mg base (as phosphate or sulfate) * For use only for the treatment of P. vivax infection
	dihydroartemisinin + piperaquine phosphate [a]	Tablet: 20 mg +160 mg, 40 mg + 320 mg [a] > 5 kg
	primaquine [a]*	Tablet: 7.5 mg, 15 mg (as diphosphate) * Only for use to achieve radical cure of P.vivax and P.ovale infections, given for 14 days. [a] not to be used in pregnant women, infants aged < 6 months and women breastfeeding infants < 6 months
	Complementary list	
	artesunate *	Injection: 60 mg (anhydrous artesunic acid) ampoule with separate ampoule of 5 % sodium bicarbonate solution. *For use in the management of severe malaria
6.5.3.2	***For chemoprevention***	
	atovaquone + proguanil	Tablet: 62.5+ 25 mg, 250 mg + 100 mg
	sulfadoxine + pyrimethamine	Tablet (dispersible) : 500 mg + 25 mg; 250 mg + 12.5 mg
	chloroquine *	Tablet:300 mg base (as phosphate or sulfate) * Recommended for prophylaxis to areas with only P. vivax transmission
	doxycycline [a] *	Solid oral dosage form: 100 mg (as hydrochloride or hyclate) [a] >8 years. * For chemoprophylaxis, not necessary for in-country travel within Nepal
	mefloquine [a] *	Tablet: 250 mg (as hydrochloride) [a] >5 kg or >3 months * For chemoprophylaxis, not necessary for in-country travel within Nepal

7 ANTIMIGRAINE MEDICINES

7.1	**For treatment of acute attack**	
	paracetamol	Tablet: 500 mg
	Complementary list	
	sumatriptan	Tablet: 50 mg
7.2	**For Prophylaxis**	
	propranolol	Tablet: 20 mg, 40 mg (hydrochloride)

8 IMMUNOMODULATORS AND ANTINEOPLASTICS

8.1	**Immunomodulators for non-malignant diseases**	
	Complementary list	
	azathioprine	Tablet: 25 mg [c], 50 mg
	ciclosporin (cyclosporine)	Capsule:25 mg
8.2	**Antineoplastic and supportive medicines**	
	Medicines listed below should be used according to protocols for treatment of the diseases.	
8.2.1	**Cytotoxic medicines**	
	Complementary list	
	arsenic trioxide	Concentrate for solution for infusion: 1 mg/mL; 2 mg/ml
	bleomycin	Powder for injection: 15 mg (as sulfate) in vial
	bendamustine	Injection: 2.5 mg (hydrochloride as lyophilized powder)/ ml in 10 ml vial
	calcium folinate (calcium leucovorin)	Tablet: 15 mg Injection: 10mg/ ml in 5 ml ampoule
	capecitabine	Tablet: 500 mg
	carboplatin	Injection: 150 mg, 450 mg in vial
	chlorambucil	Tablet: 2 mg, 5 mg
	cisplatin	Injection: 10 mg, 50 mg in vial
	cyclophosphamide	Powder for injection: 200 mg, 500 mg, 1 g in vial Tablet: 50 mg
	cytarabine	Powder for injection: 100 mg, 500 mg in vial
	dacarbazine	Powder for injection: 100 mg, 200 mg, 500 mg in vial
	dactinomycin	Powder for injection: 500 mcg in vial
	daunorubicin	Powder for injection: 20 mg (hydrochloride) in vial
	docetaxel	Injection: 20 mg/ ml, 40 mg/ ml
	doxorubicin	Liposomal injection: 50 mg Powder for injection: 10 mg, 50 mg in vial

	epirubicin	Injection: 10 mg, 50 mg
	etoposide	Capsule: 100 mg Injection: 20 mg/ ml in 5ml ampoule
	fluorouracil	Injection: 50 mg/ ml in 5 ml, 10 ml ampoule
	gemcitabine	Powder for injection: 200 mg, 1 g in vial
	hydroxyurea (hydroxycarbamide)	Capsule: 500 mg
	ifosfamide + mesna	Injection: 1 g + 200 mg in vial
	irinotecan	Injection: 20 mg/ ml
	l-asparaginase	Powder for injection: 5 000 IU, 10 000 IU in vial
	melphalan	Powder for injection: 50 mg in vial Tablet: 2 mg, 5 mg
	mercaptopurine	Tablet: 50 mg
	methotrexate	Powder for injection: 15 mg, 50 mg (as sodium salt) in vial Tablet: 2.5 mg, 5 mg, 10 mg (as sodium salt)
	mitomycin	Powder for injection: 2mg, 10mg, 20mg in vial
	oxaliplatin	Injection: 50 mg/10 ml in 10 ml vial
	paclitaxel	Powder for injection: 6 mg/ ml in vial, 25 mg,100 mg, 260 mg in vial
	procarbazine [c]	Capsule: 50 mg (as hydrochloride)
	vinblastine	Powder for injection:1 mg/ml (sulfate) in vial
	vincristine	Powder for injection:1 mg/ml (sulfate) in vial
8.2.2	**Targeted therapies**	
	Complementary list	
	All-trans retinoid acid	Capsule:10 mg
	bortezomib	Powder for injection: 2 mg, 3.5 mg in vial
	dasatinib	Tablet: 20 mg, 50 mg, 70 mg
	gefitinib	Tablet: 250 mg
	imatinib	Tablet: 100 mg, 400 mg
	rituximab	Injection (intravenous): 10 mg/ml
8.2.3	**Immunomodulators**	
	Complementary list	
	filgrastim	Injection: 300 mcg/ 0.5 ml in prefilled syringe, 300 mcg/ ml in 1 ml vial

	lenalidomide	Capsule: 25 mg
	pembrolizumab	Concentrate for solution for infusion: 25 mg/mL in 4 mL vial
	thalidomide*	Capsule: 50 mg * Contraindicated in pregnant women
8.2.4	**Hormones and antihormones**	
	Complementary list	
	abiraterone	Tablet: 250 mg, 500 mg
	bicalutamide	Tablet or capsule: 50 mg
	dexamethasone *	Injection: 4 mg (as disodium phosphate salt)/ ml in 1 ml ampoule * hydrocortisone preferred in neonates
	hydrocortisone	Powder for injection: 100 mg (as sodium succinate) in vial
	letrozole *	Tablet: 2.5 mg * Not to be used with tamoxifen
	methylprednisolone [c]	Powder for injection: 40 mg (as sodium succinate);125 mg (as sodium succinate) in vial
	prednisolone	Tablet: 5 mg, 10 mg, 20 mg
	tamoxifen	Tablet: 10 mg, 20 mg (as citrate)
8.2.5	**Supportive medicines**	
	Complementary list	
	allopurinol [c]	Powder for injection: 500 mg (as sodium) Tablet: 100 mg; 300 mg – Tumour lysis syndrome
	mesna	Injection:100 mg/ ml in 4 ml ampoule
	ondansetron [c] [a]	Injection: 2 mg (as hydrochloride)/ ml in 2 ml, 4 ml vial Oral liquid: 4 mg base/5 ml Tablet: 2 mg, 4 mg (as hydrochloride) [a] not in infants ≤ 1 month
	zoledronic acid	Solution for infusion: 4 mg/ 100 ml in 100 ml bottle

9 THERAPEUTIC PRODUCTS TO TREAT MALNUTRITION DISORDERS

f 75 therapeutic milk	Elements	For 100ml of F-75 milk
	Energy	77kcal
	Proteins	5 % of total energy
	Lipids	30% of total energy
	Fatty acid n-6	≈ 7% of total energy
	Fatty acid n-3	≈ 0.7% of total energy
	Carbohydrate	65% of total energy
	Lactose	1.2 g
	Sucrose	2.4 g
	Moisture	-
	Calcium	77 mg
	Phosphorus	77 mg
	Potassium	142 mg
	Magnesium	9.5 mg
	Zinc	2.5 mg
	Copper	0.27 mg
	Iron	<0.06 mg
	Iodine	17.9 µg
	Sodium	<17 mg
	Selenium	5.1 µg
	Vit. A	0.14-0.3 mg
	Vit. D	2.6-4.9 µg
	Vit. E	3.4-4.9 mg
	Vit. C	> 8.5 mg
	Vit. B1	> 85 µg
	Vit. B2	>0.3 mg
	Vit. B6	>0.1 mg
	Vit. B12	0.3 µg
	Vit. K	2.6-8.2 µg
	Biotin	>10 µg
	Folic acid	>34 µg
	Pantothenic acid	>0.51 mg
	Niacin	>0.85 mg
f 100 therapeutic milk	Elements	For 100ml of F-100 milk
	Energy	100 kcal
	Proteins	11 % of total energy
	Lipids	51% of total energy
	Fatty acid n-6	≈ 7% of total energy

	Fatty acid n-3 ≈ 0.6% of total energy Carbohydrate 38% of total energy Lactose 4 g Sucrose 0.2 g Moisture - Calcium 76 mg Phosphorus 76 mg Potassium 228 mg Magnesium 21 mg Zinc 2.4 mg Copper 0.3 mg Iron <0.07 mg Iodine 20 µg Sodium <56 mg Selenium 5.7 µg Vit. A 0.15-0.3 mg Vit. D 2.9-5.7 µg Vit. E 3.8-5.7 mg Vit. C > 9.5 mg Vit. B1 > 95 µg Vit. B2 >0.3 mg Vit. B6 >0.1 mg Vit. B12 0.3 µg Vit. K 2.8-9.5 µg Biotin >11 µg Folic acid >38 µg Pantothenic acid >0.57 mg Niacin >0.95 mg
ready to use therapeutic products	Sachet ; Net Weight: 92 Grams 1 sachet = 500 kcal Nutritional Contents 100g Energy (Kcal) 540 Protein (%) 10.5 Lipids (%) 55.0 Minerals 100g Sodium(mg) 100 Potassium (mg) 1213 Calcium (mg) 380 Phosphorous(mg) 430 Magnesium(mg) 115 Iron(mg) 12 Zinc(mg) 13 Copper(mg) 1.6 Selenium(µg) 30 Iodine (µg) 105 Vitamins 100g

	Vitamin A(μg)	900
	Vitamin D(μg)	17.5
	Vitamin E(μg)	30
	Vitamin K(μg)	23
	Vitamin B1(mg)	0.9
	Vitamin B2(mg)	2.1
	Vitamin C(mg)	80
	Vitamin B6(mg)	0.9
	Vitamin B12(μg)	2.3
	Folic acid(μg)	238
	Niacin(mg)	6.5
	Pantothenic acid(mg)	4.5
	Biotin(μg)	80

10 MEDICINES AFFECTING THE BLOOD

10.1	**Antianaemia medicines**	
	cyanocobalamin	Injection: 30 mcg/ ml
	ferrous salt	Oral liquid: equivalent to 9 mg iron/ ml elemental iron [c], equivalent to 25 mg iron/ ml elemental iron Tablet: equivalent to 60 mg iron
	ferrous salt + folic acid	Tablet: equivalent to 60 mg iron+ 400 mcg folic acid (nutritional supplement for use during pregnancy)
	folic acid *	Oral liquid: 1 mg/ml [c] Tablet: 5mg * Periconceptual use for prevention of first occurrence of neural tube defects
	Iron sucrose	Injection:100 mg/10 ml in 10 ml vial; 500 mg/50 ml in 50 ml vial
	Complementary list	
	erythropoietin (epo)	Injection 4K or 6K IU
10.2	**Medicines affecting coagulation**	
	apixaban	Tablet: 2.5 mg, 5 mg
	desmopressin	Injection: 4 mcg/ ml Nasal spray: 150 mcg /metered spray
	enoxaparin	Injection: 20 mg/ 0.2 ml, 60 mg/ 0.6 ml, 80 mg/ 0.8 ml
	heparin sodium [c]	Injection: 1000 IU/ ml, 5000 IU/ ml, 20 000 IU/ml in 1 ml ampoule
	phytomenadione	Injection: 1mg/ml, 10 mg / ml in 5 ml ampoule Tablet: 5 mg
	warfarin [c]	Tablet: 1mg, 2 mg, 5 mg (sodium salt)
	tranexamic acid	Injection: 100 mg/ ml in 5 ml ampoule Tablet: 500 mg
10.3	**Medicines for haemoglobinopathies**	
10.3.1	**Medicines for sickle-cell disease**	
	deferasirox	Solid oral dosage form: 250 mg, 500 mg
	deferiprone	Tablet: 500 mg

	hydroxyurea (hydroxycarbamide)	Capsule: 200mg, 500 mg
	Complementary list	
	deferoxamine	Powder for injection: 500 mg (mesilate) in vial
10.3.2	**Medicines for thalassaemias**	
	deferasirox	Solid oral dosage form: 250 mg, 500 mg
	deferiprone	Tablet: 500 mg
	Complementary list	
	deferoxamine	Powder for injection: 500 mg (mesilate) in vial

11 BLOOD PRODUCTS, COAGULATION FACTORS, AND PLASMA SUBSTITUTES

11.1	**Human Immunoglobulins**	
11.1.1	**Human immunoglobulins**	
	Anti-D immunoglobulin	Injection: 250 mcg in single dose vial
	Anti-rabies hyperimmune serum	Injection: 1000 IU in 5 ml ampoule
	Anti-tetanus immunoglobulin	Injection: 500 IU, 1000 IU/ ml, 3000 IU/ ml in vial
11.2	**Coagulation factors**	
	Complementary list	
	coagulation factor VIII	Powder for injection: 500 IU/ vial
	coagulation factor IX	Powder for injection: 500 IU/ vial, 1000 IU/ vial
11.3	**Plasma substitutes**	
	albumin, human	Injectable solution: 20% or 25%
	polygeline	Injectable solution: 3.5%

12 CARDIOVASCULAR MEDICINES

12.1	**Antianginal medicines**	
	bisoprolol	Tablet: 5 mg
	glyceryl trinitrate	Injection 1 mg/ml Tablet (sublingual): 500 mcg
	isosorbide dinitrate	Tablet (sublingual): 5 mg, 10 mg
	metoprolol	Tablet: 12.5 mg, 25 mg, 50 mg (as tartarate); 12.5 mg, 25 mg, 50 mg (as succinate)
	verapamil	Injection: 2.5 mg/ ml in 2 ml ampoule Tablet: 40 mg, 80 mg (hydrochloride)
12.2	**Antiarrhythmic medicines**	
	Complementary list	
	amiodarone	Injection: 50 mg (hydrochloride)/ ml in 3 ml ampoule Tablet: 100 mg, 200 mg
	digoxin	Injection: 250 mcg/ ml in 2 ml ampoule Oral liquid: 50 mcg/ ml Tablet: 125 mcg, 250 mcg
	epinephrine (adrenaline)	Injection: 100 mcg (as acid tartrate or hydrochloride)/ ml in 10 ml ampoule
	isoprenaline	Injection: 1 mg (hydrochloride)/ ml in vial
	lidocaine (lignocaine preservative free)	Injection: 20 mg (hydrochloride)/ ml in vial
	metoprolol	Tablet: 12.5 mg, 25 mg, 50 mg
	verapamil	Injection: 2.5 mg / ml in 2 ml ampoule
12.3	**Antihypertensive medicines**	
	amlodipine	Tablet: 2.5 mg, 5 mg (as maleate, mesylate or besylate)
	amlodipine + losartan	Tablet: 5 mg + 25 mg, 5 mg + 50 mg
	clonidine	Tablet: 200 mcg
	enalapril	Tablet: 2.5 mg, 5 mg, 10 mg, 20 mg (as hydrogen maleate)

hydralazine *	Powder for injection: 20 mg (hydrochloride) in ampoule * Hydralazine is listed for use only in the acute management of severe pregnancy-induced hypertension. Its use in the treatment of essential hypertension is not recommended in view of the evidence of greater efficacy and safety of other medicines.
hydrochlorothiazide	Tablet: 12.5 mg, 25 mg
labetalol	Injection: 5 mg/ ml in 20 ml Tablet: 50 mg
losartan	Tablet:25 mg, 50 mg
methyldopa *	Tablet: 250 mg * Methyldopa is listed for the use in the management of pregnancy induced hypertension only. Its use in the treatment of essential hypertension is not recommended in view of the evidence of greater efficacy and safety of other medicines.
nifedipine	Tablet (sustained release): 10 mg, 20 mg
prazosin	Tablet (sustained release): 500 mcg, 1 mg (mesilate)
Complementary list	
sodium nitroprusside	Powder for infusion: 50 mg in ampoule
ephedrine *	Injection: 30 mg (hydrochloride)/ ml in 1 ml ampoule * Used to prevent hypotension

12.4 Medicines used in heart failure

digoxin	Injection: 250 mcg/ ml in 2 ml ampoule Oral liquid: 50 mcg/ ml Tablet: 125 mcg, 250 mcg
furosemide [c]	Injection:10 mg/ ml in 2 ml ampoule Tablet: 20 mg, 40 mg
losartan	Tablet:25 mg, 50 mg
ramipril	Tablet: 2.5 mg, 5 mg
spironolactone	Tablet: 25 mg
Complementary list	
dobutamine	Injection: 12.5 mg (as hydrochloride)/ ml in 20 ml ampoule

	dopamine	Injection: 40 mg (hydrochloride)/ ml in 5 ml vial
	norepinephrine (noradrenaline)	Injection: 1 mg/ ml in 2 ml ampoule
12.5	**Antithrombotic medicines**	
12.5.1	**Anti-platelet medicines**	
	acetylsalicylic acid (aspirin)	Tablet: 50 mg, 75 mg, 150 mg, 300 mg
	clopidogrel	Tablet: 75 mg
12.5.2	**Thrombolytic medicines**	
	Complementary list	
	tenecteplase	Powder for injection: 20 mg; 40 mg in vial
12.6	**Lipid lowering agent**	
	atorvastatin	Tablet: 10 mg, 20 mg (as calcium trihydrate)
	fenofibrate	Tablet: 160 mg

13 DERMATOLOGICAL MEDICINES (TOPICAL)

13.1	**Antifungal medicines**	
	benzoic acid + salicylic acid	Ointment or cream: 6% + 3% w/w
	clotrimazole	Cream: 1% w/w
13.2	**Anti-infective medicines**	
	povidone iodine	Solution: 5% w/v
	silver sulfadiazine [a]	Cream: 0.2%, 1% [a] Not in neonates ≤ 2 months
	Complementary list	
	mupirocin	Cream or ointment: 2%
	fusidic acid	Cream: 2%
13.3	**Anti-inflammatory and antipruritic medicines**	
	calamine	Lotion: 15% w/v
	Complementary list	
	betamethasone [a]	Ointment or cream: 0.1% (as valerate) [a] Hydrocortisone preferred in neonates
	hydrocortisone	Ointment or cream: 1% w/w (acetate)
13.4	**Medicines affecting skin differentiation and proliferation**	
	benzoyl peroxide	Cream or lotion: 5%
	salicylic acid	Cream: 10%
	Complementary list	
	fluorouracil	Ointment: 5%
	podophyllotoxin	Solution: 0.5% w/v in 3.5 ml bottle
13.5	**Scabicides and pediculicides**	
	permethrin	Lotion: 1%, 5%

	benzyl benzoate [a]	Lotion: 25% w/v [a] not in children ≤ 2 years
13.6	**Humectants**	
	glycerol	Solution: 15% to 20%
	urea	Cream: 5%

14 DIAGNOSTIC AGENTS

14.1	**Ophthalmic medicines**	
	fluorescein	Eye drops: 1%, 2% (sodium salt) Injection: 10%, 20% (sodium salt) in 5 ml ampoule
14.2	**Radiocontrast media**	
	Complementary list	
	amidotrizoate	Injection: 140-420 mg iodine (as sodium or meglumine salt)/ ml in 20 ml, 50 ml ampoule
	barium sulfate [c]	Aqueous suspension: 100-250% w/v
	iohexol	Injection: 140-350 mg iodine/ ml in 10 ml, 20 ml ampoule or 50 ml vial
	Complementary list	
	meglumine iotroxate	Solution: 5 g- 8 g iodine in 100-250 ml

15 DISINFECTANTS AND ANTISEPTICS

15.1	**Antiseptics**	
	chlorhexidine	Solution: 5% (digluconate)
	ethanol (rectified spirit)	Liquid: 70% (denatured)
	povidone iodine	Solution: 10 % w/v (equivalent to 1% available iodine)
15.2	**Disinfectants**	
	alcohol based hand rub	Solution: containing ethanol 80% v/v Solution: containing isopropyl alcohol 75% v/v
	chlorine based compound	Powder for solution: 0.1% available chlorine
	glutaraldehyde	Solution: 2%
	hypoclorous acid	Solution (aqueous): containing hypochlorous acid ≥ 150 parts per million

16 DIURETICS

furosemide	Injection:10 mg/ ml in 2 ml ampoule Tablet: 40 mg
hydrochlorothiazide	Solid oral dosage form: 25mg [c], 50 mg
mannitol [c]	Injectable solution: 10%, 20%
spironolactone [c]	Tablet:25 mg, 100 mg

17 GASTROINTESTINAL MEDICINES

17.1	**Antacids and antiulcer medicines**	
	omeprazole	Capsule:20 mg Powder for oral liquid: 20 mg; 40 mg sachet
	ranitidine	Injection: 25 mg (as hydrochloride)/ ml in 2 ml ampoule Tablet: 150 mg, 300 mg (as hydrochloride)
	Complementary list	
	pantoprazole	Injection 40 mg
17.2	**Antiemetic medicines**	
	domperidone	Suspension: 1 mg/ ml Tablet: 10 mg
	ondansetron [c] [a]	Injection: 2 mg (as hydrochloride)/ ml in 2 ml, 4 ml vial Oral liquid: 4 mg base/5 ml Tablet: 2 mg, 4 mg (as hydrochloride) [a] not in infants ≤ 1 month
	metoclopramide [a] *	Injection: 4 mg (as disodium phosphate salt)/ ml in 1 ml ampoule * hydrocortisone preferred in neonates
	Complementary list	
	aprepitant	Capsule: 80 mg; 125 mg; 165 mg; Powder for oral suspension: 125 mg sachet
17.3	**Anti-inflammatory medicines**	
	sulfasalazine	Tablet: 500 mg
17.4	**Laxatives**	
	lactulose [c] *	Solution: 3.35 mg / 5 ml
	magnesium sulfate	Powder: 500 g
	Complementary list	
	bisacodyl	Tablet: 5 mg , 10 mg
	ispaghula husk	Oral powder
17.5	**Medicines used in diarrhea**	
17.5.1	Oral rehydration	

	oral rehydration salts *	ORS Powder for dilution in 1 L (as per WHO recommended formula)
17.5.2	Medicine for diarrhoea	
	zinc sulfate *	Tablet (dispersible): equivalent to zinc 10 mg, 20 mg (scored) * In acute diarrhoea, zinc sulfate should be used as an adjunct to oral rehydration salts
17.6	**Antispasmodic medicines**	
	hyoscine butylbromide [c] *	Injection: 20 mg/ ml in 1 ml ampoule Tablet: 10 mg, 20 mg
	Complementary list	
	drotaverine hydrochloride	Tablet: 40 mg, 80 mg

18 MEDICINES FOR ENDOCRINE DISORDERS

18.1	**Adrenal hormones and synthetic substitutes**	
	dexamethasone *	Injection: 4 mg (as disodium phosphate salt)/ml in 1 ml ampoule Tablet: 500 mcg, 4 mg
	hydrocortisone	Powder for injection: 100 mg (as sodium succinate) in vial Tablet:10 mg, 20 mg
	prednisolone	Syrup 15 mg/ml Tablet: 5 mg, 10 mg, 20 mg
	Complementary list	
	fludrocortisone	Tablet: 100 mcg (acetate)
18.2	**Androgens**	
	Complementary list	
	testosterone	Injection: 200 mg in 1 ml ampoule
18.3	**Estrogens**	
	ethinylestradiol	Tablet: 50 mcg
18.4	**Progestogens**	
	norethisterone	Tablet: 5 mg
	medroxyprogesterone acetate	Tablet: 5 mg
18.5	**Medicines for diabetes**	
18.5.1	**Insulins**	
	insulin glargine	Injection: 100 IU/ml in 3 ml cartridgel
	insulin (rapid acting)	Injection solution: 100 IU/ml in 10 ml vial; 100 IU/ml in 3 ml cartridge or pre-filled pen.
	insulin (soluble)	Injection: 40 IU / ml in 10 ml vial
	intermediate acting insulin (NPH)	Injection: 40 IU/ ml in 10 ml vial (as compound insulin zinc suspension or isophane insulin)
	premixed insulin	Injection: 30/70

18.5.2	**Oral hypoglycemic agent**	
	dapagliflozin [a]	Tablet: 5mg, 10 mg >10 years (Safety not established in children below 10 years)
	gliclazide	Tablet: 40 mg, 80 mg
	metformin [c]	Tablet: 500 mg, 850 mg, 1 g(hydrochloride); 1 g SR
	Complementary list	
	glipizide	Tablet: 2.5 mg, 5 mg
	semaglutide	Injection solution: 0.68 mg/ml; 1.34 mg/ml
18.6	**Thyroid hormones and antithyroid medicines**	
	carbimazole [c]	Tablet: 5 mg
	levothyroxine	Tablet: 25 mcg [c], 50 mcg, 75 mcg, 100 mcg (sodium salt)
	lugol's iodine [c]	Oral solution: iodine 5% + potassium iodide 10%
	propylthiouracil	Tablet: 50 mg
18.7	**Posterior pituitary hormone**	
	desmopressin [c]	Injection: 4 mcg/ ml Nasal spray: 150 mcg /metered spray
18.8	**Medicines for disorders of the pituitary hormone system**	
	octreotide	Injection: 100 mcg

19 IMMUNOLOGICALS

19.1	**Diagnostic agents**	
	tuberculin, purified protein derivative (PPD)	Injection
19.2	**Sera and immunoglobulins**	
	diphtheria antitoxin (immunoglobulin)	Injection: 10000 IU, 20000 IU in vial
	equine rabies immunoglobulin (erig)	Injection: 200 IU/ml or 300 IU/ml in vial
	polyvenom antisnake serum	Injection in vial
	tetanus antitoxin (immunoglobulin)	Injection: 1000 IU/ ml, 3000 IU/ ml in vial
19.3	**Vaccines**	
19.3.1	**For universal immunization**	
	BCG	Vaccine
	diphtheria, tetanus, pertussis, hepatitis B, haemophilus influenzae type b	Vaccine (pentavalent)
	human papilloma vaccine (HPV)	Vaccine
	japanese encephalitis vaccine	Vaccine
	measles rubella (MR)	Vaccine
	poliomyelitis (oral)	Vaccine
	poliomyelitis (inactivated)	Vaccine
	pneumococcal	Vaccine
	rotavirus	Vaccine
	tetanus diphtheria (Td)	Vaccine
19.3.2	**For specific groups of individuals**	
	Complementary list	
	hepatitis A	Vaccine
	hepatitis B	Vaccine
	Haemophilus influenzae type b	Vaccine

influenza (seasonal)	Vaccine
meningococcal meningitis	Vaccine
measles	Vaccine
mumps	Vaccine
rubella	Vaccine
tetanus toxoid	Vaccine
typhoid	Vaccine
yellow fever	Vaccine
rabies vaccine, freeze dried	Vaccine

20 MUSCLE RELAXNTS (PERIPHERALLY ACTING) AND CHOLINESTERASE INHIBITORS

neostigmine	Injection: 500 micrograms in 1 ml ampoule; 2.5 mg (metilsulfate) in 1 ml ampoule Tablet: 15 mg (bromide)
suxamethonium (succinylcholine)	Injection: 50 mg (chloride)/ ml in 10 vial
vecuronium [c]	Powder for injection: 4 mg, 10 mg (bromide) in vial
Complementary list	
atracurium	Powder for injection: 10 mg (besylate)/ ml
pyridostigmine	Tablet 60 mg, 180 mg SR Tablets

21 OPTHALMOLOGICAL PREPARATIONS

21.1	**Anti-infective agents**	
	aciclovir	Ointment: 3% W/W
	ciprofloxacin	Eye ointment: 0.3% Solution (eye/ ear drops): 0.3% (as hydrochloride)
	flurbiprofen	Eye Drops: 0.3% w/v
	natamycin	Suspension (eye drop): 5%
	Complementary list	
	chloramphenicol	Eye ointment: 1% w/w Solution (eye drop): 0.5%
	fluconazole	Solution (eye drop): 0.3%
	ofloxacin	Solution (eye drop): 0.3%
	tetracycline	Ointment (eye): 1% (hydrochloride)
21.2	**Anti-inflammatory agents**	
	prednisolone	Solution (eye drops): 0.5% (sodium phosphate)
21.3	**Local anaesthetics**	
	lidocaine (lignocaine)	Injection (topical): 2%, 4%
	proparacaine	Solution (eye drops): 0.5%
	Complementary list	
	tetracaine [a]	Solution (eye drops): 0.5% [a] Not in neonates
21.4	**Miotics and antiglaucoma medicines**	
	acetazolamide	Tablet: 250 mg
	latanoprost	Solution (eye drops): 0.005%

	pilocarpine	Solution (eye drops): 2%, 4% (hydrochloride)
	timolol	Solution (eye drops): 0.5 % (maleate)
21.5	**Mydriatics**	
	atropine [a]	Solution (eye drops): 1% (sulfate) [a] >3 months
	tropicamide	Solution (eye drop): 0.5%

22 MEDICINES FOR REPRODUCTIVE HEALTH AND PERINATAL CARE

22.1	**Contraceptives**	
22.1.1	**Oral hormonal contraceptives**	
	ethinylestradiol + levonorgestrel	Tablet: 30 mcg + 150 mcg, 20 mcg + 1.0 mg
	ethinylestradiol + norethisterone	Tablet: 35 mcg + 1 mg
	levonorgestrel	Tablet: 750 mcg (pack of two), 1.5 mg
22.1.2	**Injectable hormonal contraceptive**	
	medroxyprogesterone acetate	Injection (Depot intramuscular): 150 mg / ml in 1 ml vial
22.1.3	**Intrauterine devices**	
	copper-containing devices	
22.1.4	**Barrier methods**	
	condoms	
22.1.5	**Implantable contraceptives**	
	intrauterine device with progesterone	
	levonorgestrel releasing implant	Two-rod levonorgestrel-releasing implant: each rod containing 75 mg of levonorgestrel (150 mg total)
22.1.6	**Miscellaneous**	
	ring pessary	
	silicon ring pessary	
22.2	**Ovulation inducers**	
	clomifene	Tablet: 50 mg (citrate)

22.3	**Uterotonics**	
	methylergometrine	Injection: 200 mcg (maleate)/ ml in ampoule
	oxytocin	Injection: 5 IU/ ml, 10 IU/ ml in 1 ml ampoule
	Complementary list	
	carbetocin	Injection: 100 mcg/ml
22.4	**Medicines for medical abortion**	
	mifepristone * - misoprostol	Tablet: 200 mg – tablet: 200 mcg * Copackage containing: [1] tablet of mifepristone and [4] tablet of misoprostol. Requires close medical supervision. Approved for abortion services only in listed sites.
	misoprostol *	Tablet: 200 mcg, 600 mcg - Management of incomplete abortion and miscarriage - Prevention and treatment of postpartum haemorrhage where oxytocin is not available or cannot be safely used Tablet (vaginal): 25 mcg * Only for used for induction of labour where appropriate facilities are available.
22.5	**Antioxytocics (tocolytics)**	
	nifedipine	Capsule (immediate release): 10 mg
	Complementary list	
	terbutaline	Injection: 0.5 mg / ml
22.6	**Other medicines administered to the mother**	
	dexamethasone	Injection: 4 mg (as disodium phosphate salt)/ ml in 1 ml ampoule
	multiple micronutrient supplement	Tablet containing: Vitamin A (retinol acetate) 800 micrograms retinol activity equivalent Vitamin C (ascorbic acid) 70 mg Vitamin D (cholecalciferol) 5 micrograms (200 IU) Vitamin E (alpha tocopherol succinate) 10 mg alpha tocopherol equivalent Vitamin B1 (thiamine mononitrate) 1.4 mg Vitamin B2 (riboflavin) 1.4 mg Vitamin B3 (niacinamide) 18 mg niacin

		equivalent Vitamin B6 (pyridoxine hydrochloride) 1.9 mg Folic acid (folic acid) 680 micrograms dietary folate equivalent (400 micrograms) Vitamin B12 (cyanocobalamin) 2.6 micrograms Iron (ferrous fumarate) 30 mg Iodine (potassium iodide) 150 micrograms Zinc (zinc oxide) 15 mg Selenium (sodium selenite) 65 micrograms Copper (cupric oxide) 2 mg *For use in specific contexts. Refer to current WHO recommendations.
	tranexamic acid	Injection: 100 mg/ ml in 10 ml ampoule
22.7	**Medicines administered to the neonate [c]**	
	caffeine citrate [c]	Injection: 20mg/ ml (equivalent to 10 mg caffeine base/ ml) Oral liquid: 20 mg/ ml (equivalent to 10 mg caffeine base/ ml)
	chlorhexidine [c]	Solution or gel: 7.1% (digluconate) delivering 4% chlorhexidine (for umbilical cord care)
	Complementary list	
	ibuprofen [c]	Solution for Injection: 5 mg/ ml
	prostaglandin E1 [c]	Solution for injection: 0.5 mg/ml in alcohol
	surfactant [c]	Suspension for intratracheal instillation: 25 mg/ ml

23 PERITONEAL DIALYSIS SOLUTION

intraperitoneal dialysis solution (of appropriate composition)	Solution: of appropriate composition in accordance with local clinical guidelines

24 MEDICINES FOR MENTAL AND BEHAVIOURAL DISORDER

24.1	**Medicines used in psychotic disorders**	
	chlorpromazine	Injection: 25 mg (hydrochloride)/ ml in 2 ml ampoule Oral liquid: 25 mg (hydrochloride)/ 5ml Tablet: 50 mg, 100 mg (hydrochloride)
	fluphenazine	Injection:25 mg (decanoate or enantate) in 1 ml ampoule
	haloperidol *	Injection: 5 mg/ ml in 1 ml ampoule Tablet: 0.5 mg, 2 mg, 5 mg
	olanzapine	Depot preparation Powder for injection: 10 mg in vial Tablet: 2.5 mg, 5 mg, 10 mg
	risperidone	Tablet: 0.5mg, 1 mg, 2 mg, 4 mg
24.2	**Medicines used in mood disorders**	
24.2.1	**Medicines used in depressive disorders**	
	amitriptyline *	Tablet: 10 mg, 25 mg , 75 mg (hydrochloride)
	escitalopram	Solid oral dosage form:10 mg
	fluoxetine [c] [a]	Solid oral dosage form: 20 mg (as hydrochloride) [a] >8 years
24.2.2	**Medicines used in bipolar disorders**	
	carbamazepine	Tablet (scored): 100 mg, 200 mg
	lithium carbonate	Solid oral dosage form:300 mg (sustained release)
	valproic acid (sodium valproate)	Oral liquid: 200 mg/5 ml Tablet (enteric coated): 200 mg, 500 mg (sodium salt)
24.3	**Medicines used in generalized anxiety and sleep disorders**	
	clonazepam	Tablet: 0.25 mg
	diazepam	Tablet: 2 mg, 5 mg

	lorazepam	Injection: 4 mg/ml Tablet: 0.5 mg, 1 mg, 2 mg
	propranolol	Tabet: 10 mg
24.4	**Medicines used for obsessive compulsive disorders**	
	fluoxetine [c] [a]	Solid oral dosage form:20 mg (as hydrochloride) [a] > 8 years
24.5	**Medicines used in disorders due to psychoactive substance use**	
	methadone	Concentrate for oral liquid:5 mg/ ml, 10 mg/ ml (hydrochloride) Oral liquid:5 mg / 5 ml, 10 mg/ 5 ml Tablet: 5 mg
	nicotine replacement therapy (NRT)	Chewing gum: 2 mg; 4 mg (as polacrilex).
	Complementary list	
	acamprosate calcium	Tablet: 333mg
	buprenorphine *	Sublingual Tablet: 200 mcg * The medicines should only be used within an established support programme
	chlordiazepoxide	Tablet: 10 mg, 25 mg
	nicotine replacement therapy (NRT)	Transdermal patch: 5 mg to 30 mg/16 hrs; 7 mg to 21 mg/ 24 hrs

25 MEDICINES ACTING ON THE RESPIRATORY TRACT

25.1	Antiasthmatic and medicines for chronic obstructive pulmonary disease	
	budesonide (a) & formoterol (b)	Inhalation (aerosol): 100 mcg (A) + 6 mcg (B), Inhalation 200 mcg (A)+ 2 mcg (B) / metered dose
	epinephrine (adrenaline)	Injection: 1 mg (as hydrochloride or acid tartrate) in 1 ml ampoule
	hydrocortisone	Injection (sodium succinate): 100 mg, 200 mg in vial Tablet: 10 mg
	ipratropium bromide	Inhalation (aerosol): 20 mcg/ metered dose
	salbutamol	Inhalation: 100 mcg/dose Injection: 500 mcg / ml in 1ml, 5 ml ampoule Metered dose inhaler (aerosol): 200 mcg (as sulfate) per dose Oral liquid: 2mg (as sulfate)/5ml Tablet: 2 mg, 4 mg (as sulfate)
	Complementary list	
	beclomethasone	Inhalation (aerosol): 50 mcg (as dipropionate) per dose (CFC free forms)

26 SOLUTION CORRECTING WATER, ELECTROLYTE AND ACID-BASE DISTURBANCES

26.1	**Oral**	
	oral rehydration salts	ORS Powder for dilution in 1 L (as per WHO recommended formula)
26.2	**Parenteral**	
	compound solution of sodium lactate (ringer's lactate)	Injectable solution
	glucose	Injectable solution: 5% isotonic, 25% hypertonic, 50% hypertonic
	glucose with sodium chloride	Injectable solution: 5% glucose + 0.9% sodium chloride
	potassium chloride	Injection: 15% in 20 ml ampoule
	sodium chloride	Injectable solution: 0.9% isotonic (normal saline)
	sodium bicarbonate (sodium hydrogen carbonate)	Injectable solution: 7.5 % solution in 10 ml ampoule [c]
26.3	**Miscellaneous**	
	water for injection	Injection: 5 ml, 10 ml ampoule

VITAMINS AND MINERALS

ascorbic acid	Tablet: 500 mg
calcium	Tablet: 500 mg (elemental)
colecalciferol [c]	Capsule: 1 000 IU Oral liquid (drops): 400 IU/ ml Tablet (chewable): 60 000 IU
multiple micronutrient powder	Sachets containing: Per gram Vitamin A (Vitamin A acetate) 400 microgram Vitamin B1 (Thiamine mononitrate) 0.5 mg Vitamin B2 (Riboflavin) 0.5 mg Vitamin B3 (Nicotinamide) 6 mg Vitamin B6 (Pyridoxine) 0.5 mg Vitamin B12 (Cyanocobalamin) 0.9 microgram Vitamin C (ascorbic acid) 30 mg Vitamin D (Cholecalciferol) 5 microgram Vitamin E (Tocopherol acetate) 5 mg Folic acid 90 microgram Copper (Cupric gluconate) 0.56 mg Iodine (Potassium iodide) 90 microgram Iron (Ferrous fumarate) 10 mg Zinc (Zinc Gluconate) 4.1 mg Selenium 17 microgram maltodextrin (base)
pyridoxine	Tablet: 25 mg (hydrochloride)
retinol	Capsule: 20 000 IU (as palmitate) Injection (water miscible): 100 000 IU (as palmitate) in 2 ml ampoule Oral solution (oil): 100 000 IU (as palmitate)/ ml in multi-dose dispenser
riboflavin	Tablet: 5 mg
sodium bicarbonate	Injectable solution: 7.5 % solution in 10 ml ampoule [c] Tablets: 500 mg, 1 g
thiamine	Tablet: 100 mg (as hydrochloride)
Complementary list	
calcium gluconate	Injection:100 mg/ ml in 10 ml ampoule

28 EAR, NOSE AND THROAT MEDICINES

acetic acid	Topical: 2%, in alcohol
betamethasone	Ear drop or cream: 0.05 %
chloramphenicol	Ear drop: 5%
ciprofloxacin [c]	Ear drop: 0.3% (as hydrocholoride)
clotrimazole	Ear drop: 1%
lidocaine (lignocaine)	Topical (viscous): 2%, 4%
mometasone furoate	Nasal spray (aqueous): 50 mcg per spray
oxymetazoline [c] [a]	Solution (nasal drops): 0.025%, 0.05% [a] > 6 years
sodium bicarbonate + glycerin	Ear drop: 1% + 5%

29 MEDICINES FOR DISEASES OF JOINTS

29.1	**Medicines used to treat gout**	
	allopurinol	Tablet: 100 mg, 300 mg
	colchicine	Tablet: 500 mcg
29.2	**Disease modifying agents used in rheumatic disorders (DMARDs)**	
	methotrexate	Tablet: 2.5 mg, 5 mg, 10 mg (as sodium salt)
	Complementary list	
	azathioprine	Tablet: 25 mg, 50 mg
	hydroxychloroquine	Solid oral dosage form: 200 mg

30 DENTAL MEDICINES AND PREPARATIONS

benzocaine	Ointment: 0.2% Solution: 20%
chlorhexidine	Solution: 0.2% (gluconate)
fluoride	Varnish: containing 22 500 ppm fluoride
lidocaine (lignocaine)	Injection: 1%, 2% (hydrochloride) in vial Spray: 5-10% Topical (sterile): 2% w/w
lidocaine (lignocaine) + epinephrine (adrenaline)	Injection: 2% (as hydrochloride or sulfate) + epinephrine 1: 200 000 in vial
zinc oxide	Powder

Annex I

Summary of changes reflected in National List of Essential Medicines, 2026										
S.N.	**Section Title**	**Molecule Name**	**Dosage Form**	**Strength**	**List (Main/Comp)**	**Added/ Deleted**	**Molecule**	**Dosage Form**	**Strength**	**Reason**
1.1.1	Inhalational medicines	halothane	Inhalation (aerosol)	Not Applicable	M	Deletion	1	1	-	Not used anymore, owing to better alternatives.
1.1.1	Inhalational medicines	sevoflurane	Inhalation (aerosol)	Not Applicable	M	Modification	1	1	1	Shifted from complementary to core list due to increasing clinical utility
1.2	Local anaesthetics	lidocaine (lignocaine)	Injection	0.5% [c]	M	Line Extension	1	1	1	New Injection strength specific for children.
1.3	Preoperative medication and sedation for short-term procedures	atropine	Injection	400 micrograms/ ml [c]	M	Line Extension	1	1	1	New Injection strength specific for children.
1.3	Preoperative medication and sedation for short-term procedures	morphine	Injection	1 mg/ml [c]; 2 mg/ml [c]	M	Line Extension	1	1	2	New Injection strength specific for children.
2.3	Medicines for other common symptoms in palliative care	amitriptyline	Tablet	10 mg, 25 mg, 75 mg	M	Modification	1	1	3	Created a sub-section in line with WHO EML and Nepal is developing National Strategy for Palliative Care 2025-35

2.3	Medicines for other common symptoms in palliative care	dexamethasone	Injection, Tablet	4 mg (as disodium phosphate salt)/ml in 1 ml ampoule 500 mcg, 4 mg	M	Modification	1	2	3	Created a sub-section in line with WHO EML and Nepal is developing National Strategy for Palliative Care 2025-35
2.3	Medicines for other common symptoms in palliative care	diazepam	Injection, Tablet	5 mg/ml in 2 ml ampoule; 5 mg, 10 mg	M	Modification	1	2	3	Created a sub-section in line with WHO EML and Nepal is developing National Strategy for Palliative Care 2025-35
2.3	Medicines for other common symptoms in palliative care	fluoxetine	Solid oral dosage form	20 mg (as hydrochloride)	M	Modification	1	1	1	Created a sub-section in line with WHO EML and Nepal is developing National Strategy for Palliative Care 2025-35
2.3	Medicines for other common symptoms in palliative care	haloperidol	Injection, Tablet	5 mg/ ml in 1 ml ampoule; 0.5 mg, 2 mg, 5 mg	M	Modification	1	2	4	Created a sub-section in line with WHO EML and Nepal is developing National Strategy for Palliative Care 2025-35
2.3	Medicines for other common symptoms in palliative care	hyoscine butylbromide	Injection, Tablet	20 mg/ ml in 1 ml ampoule; 10 mg, 20 mg	M	Modification	1	2	3	Created a sub-section in line with WHO EML and Nepal is developing National Strategy for Palliative Care 2025-35

2.3	Medicines for other common symptoms in palliative care	lactulose	Solution	3.35 g / 5 ml	M	Modification	1	1	1	Created a sub-section in line with WHO EML and Nepal is developing National Strategy for Palliative Care 2025-35
2.3	Medicines for other common symptoms in palliative care	loperamide	Solid oral dosage form	2 mg	M	Addition	1	1	1	Widely used in non-infective diarrhea
2.3	Medicines for other common symptoms in palliative care	metoclopramide	Injection, Tablet	5 mg (hydrochloride)/ ml in 2 ml ampoule; 10 mg (hydrochloride)	M	Modification	1	2	2	Created a sub-section in line with WHO EML and Nepal is developing National Strategy for Palliative Care 2025-35
2.3	Medicines for other common symptoms in palliative care	midazolam	Injection	1 mg/ ml, 5 mg/ ml	M	Modification	1	1	2	Created a sub-section in line with WHO EML and Nepal is developing National Strategy for Palliative Care 2025-35
2.3	Medicines for other common symptoms in palliative care	ondansetron	Injection Oral liquid Tablet	2 mg (as hydrochloride)/ ml in 2 ml, 4 ml vial; 4 mg base/5 ml; 2 mg, 4 mg (as hydrochloride)	M	Modification	1	3	3	Created a sub-section in line with WHO EML and Nepal is developing National Strategy for Palliative Care 2025-35

3	Antiallergics and medicines used in anaphylaxis	dexamethasone	Oral liquid, Tablet	2 mg/5 mL (as sodium phosphate); 2 mg; 4 mg (as dexamethasone base)	M	Line Extension	1	2	3	New dosage form and strength specific for children
4.2	Specific antidotes	protamine sulfate	Injection	10 mg/ ml in 5 ml ampoule	M	Modification	1	1	1	Shifted from Section 10
4.2	Specific antidotes	succimer	Solid oral dosage form	100 mg	C	Addition	1	1	1	Antidote for Lead poisoning
5.1.1	Antiseizure medicines	lamotrigine	Tablet	25 mg, 50 mg, 100 mg, 200 mg	M	Addition	1	1	1	For use as adjunctive therapy for treatment-resistant partial or generalized seizures
5.1.1	Antiseizure medicines	levetiracetam	Oral solution, Tablet	100 mg/ml; 250 mg, 500 mg	C	Addition	1	2	3	Broad-spectrum antiseizure medication and safest teratogenic profile
5.1.1	Antiseizure medicines	phenobarbital	Oral liquid	15 mg/5 ml	M	Line Extension	1	1	1	Crucial for accurate dosing in children and essential for patients with difficulty in swallowing
5.1.1	Antiseizure medicines	phenytoin	Oral liquid	30 mg/5 ml	M	Line Extension	1	1	1	Crucial for accurate dosing in children and essential for patients with difficulty in swallowing
5.1.1	Antiseizure medicines	prednisolone	Oral liquid, Tablet	1 mg/ml; 1 mg, 5 mg, 10 mg	M	Modification	1	2	4	Medicine present in section 3 also added under 5.1.1 in line with WHO EML

5.1.1	Antiseizure medicines	valproic acid (sodium valproate)	Injection	100 mg/ml	C	Line Extension	1	1	1	Emergency treatment of epilepsy seizures and for rapid response in status epilepticus
5.1.2	Medicines for multiple sclerosis	rituximab	Injection	10 mg/ml	C	Addition	1	1	2	Treatment of multiple sclerosis
5.1.3	Medicines for parkinsonism	levodopa + carbidopa	Tablet	100 mg + 10 mg, 250 mg + 25 mg	M	Modification	2	1	2	Shifted from section 9 to sub-section 5.3 in line with WHO EML formatting
5.1.3	Medicines for parkinsonism	trihexyphenidyl (benzhexol)	Tablet	2 mg (hydrochloride)	M	Modification	1	1	1	Shifted from section 9 to sub-section 5.3 in line with WHO EML formatting
5.1.4	Medicines for cerebral palsy	baclofen	Tablet	10 mg	C	Addition	1	1	1	Created a sub-section in line with WHO EML
5.2.1	Medicines for myasthenia gravis	neostigmine	Injection, Tablet	500 micrograms in 1 ml ampoule; 2.5 mg (metilsulfate) in 1 ml ampoule; 15 mg (bromide)	M	Modification	1	2	3	Created a sub-section in line with WHO EML
5.2.1	Medicines for myasthenia gravis	pyridostigmine	Tablet	mg, 180 mg SR Tablets	C	Addition	1	1	2	Created a sub-section in line with WHO EML
6.1.2	Antifilarials	ivermectin	Solid oral dosage forms	3mg	M	Modification	1	1	1	Shift in treatment algorithm

6.1.2	Antifilarials	diethylcarbamazine	Solid oral dosage forms	150 mg	M	Line Deletion	1	1	2	Shift in treatment algorithm
6.2.1	Access group antibiotics	amoxicillin + clavulanic acid	Powder for injection, Tablet	500 mg (as sodium) + 100 mg (as potassium salt); 1000 mg (as sodium) + 200 mg (as potassium salt) in vial; 500 mg (as trihydrate) + 125 (as potassium salt)mg, 875 mg (as trihydrate) + 125 (as potassium salt) mg	M	Modification	1	2	4	Shifted from Section 6.2.2 Watch Group Antibiotics to 6.2.1 Access Group Antibiotics
6.2.1	Access group antibiotics	nalidixic acid	Solid oral dosage form	250 mg, 500 mg	M	Deletion	1	1	2	High resistance, better alternatives available
6.2.1	Access group antibiotics	doxycycline	Capsule, Oral liquid, Powder for injection, Solid oral dosage form	100 mg (as hydrochloride); 25 mg/ 5 ml [c], 50 mg/ 5 ml [c] (anhydrous); 100 mg in vial: 50 mg [c], 100 mg (hyclate)	M	Modification	1	4	6	Use case added for scrub typhus

6.2.2	Watch group antibiotics	ceftazidime	Injection	250mg, 500mg, 1g, 2g	C	Addition	1	1	4	To address antibiotic need
6.2.2	Watch group antibiotics	ciprofloxacin	Solution for IV infusion	2 mg/mL (as hyclate) [c]	M	Line Extension	1	1	1	New Injection strength specific for children
6.2.2	Watch group antibiotics	azithromycin	Oral liquid Solid oral dosage form	200 mg/ 5 ml; 250 mg, 500 mg (anhydrous)	M	Modification	1	2	3	Use case added for scrub typhus
6.2.3	Reserve group antibiotics	fosfomycin sulfate	Solid oral dosage form; Injection	Sachet 3g; 2g/4g IV vials	C	Addition	1	2	3	To address antibiotic need
6.2.5	Antituberculosis medicines	amikacin	Powder for injection	100 mg, 500 mg, 1 g	C	Deletion only for this category	1	1	3	Shift in treatment algorithm
6.2.5	Antituberculosis medicines	pretomanid	Tablet	200 mg	C	Addition	1	1	1	To address the National TB program
6.2.5	Antituberculosis medicines	rifapentine	Tablet	150 mg, 300 mg; Tablet (dispersible, scored): 150 mg [c]	M	Addition	1	1	3	To address the National TB program
6.2.5	Antituberculosis medicines	streptomycin	Powder for injection	1 g	C	Deletion	1	1	1	Shift in treatment algorithm
6.4.2.2	Non-nucleoside reverse transcriptase inhibitors	efavirenz (efv or efz)	Tablet	200 mg, 600 mg	M	Deletion	1	1	2	Shift in treatment algorithm

6.4.2.2	Non-nucleoside reverse transcriptase inhibitors	nevirapine	Tablet	200 mg	M	Line Deletion	1	1	1	Shift in treatment algorithm
6.4.2.3	Protease inhibitors	darunavir	Tablet	75mg, 400mg, 800 mg	M	Line Extension	1	1	3	Coverage of pediatric population, offer dosing flexibility
6.4.2.4	Integrase inhibitors	dolutegravir	Dispersible Tablet	10 mg	M	Line Extension	1	1	1	Coverage of pediatric population, offer dosing flexibility
6.4.2.4	Integrase inhibitors	raltegravir	Granules for oral suspension	100 mg	M	Modification	1	1	1	Better alternative to tablet dosage form
6.4.2.5	Fixed-dose combinations	abacavir + lamivudine	Tablet	600 mg + 300 mg	M	Line Deletion	2	1	1	No longer recommended, safety concerns
6.4.2.5	Fixed-dose combinations	efavirenz + lamivudine + tenofovir	Tablet	600 mg + 300 mg + 300 mg	M	Deletion	3	1	1	Shift in treatment algorithm
6.4.2.5	Fixed-dose combinations	lamivudine + nevirapine + zidovudine	Tablet	30 mg + 50 mg + 60 mg, 150 mg +200 mg + 300 mg	M	Deletion	3	1	2	Shift in treatment algorithm
6.4.4.2.1	Pangenotypic direct-acting antiviral combinations	daclatasvir +sofosbuvir	Tablet	60 mg + 400 mg	M	Addition	2	1	1	Shift in treatment algorithm
6.4.4.2.1	Pangenotypic direct-acting antiviral combinations	sofosbuvir + velpatasvir	Tablet	200 mg + 50 mg	M	Line Extension	1	1	1	Coverage of pediatric population, offer dosing flexibility
6.4.4.2.2	Pangenotypic direct-acting antiviral combinations	sofosbuvir	Granules	200 mg in sachet [c]	M	Line Extension	1	1	1	Added pediatric granules

6.5.2	Antileishmaniasis medicines	miltefosine	Capsule	50 mg	M	Modification	1	1	1	Shifted from complementary to core list
6.5.3	Antileishmaniasis medicines	paromomycin	Injection	375 mg/ ml	M	Modification	1	1	1	Shifted from complementary to core list
6.5.3.1	For curative treatment	artemether	Injection (oil)	80 mg/ ml	M	Deletion	1	1	1	Shift in treatment algorithm
6.5.3.1	For curative treatment	artesunate	Rectal (suppository) form	100 mg	C	Line Deletion	1	1	1	Better alternatives available
6.5.3.1	For curative treatment	dihydroartemisinin + piperaquine phosphate	Tablet	20 mg +160 mg	M	Line Extension	2	1	1	Coverage of pediatric population
6.5.3.1	For curative treatment	quinine	Injection; Tablet	300 mg (as dihydrochloride)/ ml in 2 ml ampoule; 300 mg (as bisulfate or sulfate)	C	Deletion	1	2	2	Shift in treatment algorithm
6.5.3.2	For chemoprevention	sulfadoxine + pyrimethamine	Tablet	500 mg + 25 mg,250 mg+12.5 mg	M	Line Extension	2	1	1	Shifted from curative to chemoprevention of malaria
7.1	For treatment of acute attack (ANTIMIGRAINE)	sumatriptan	Tablet	50 mg	C	Addition	1	1	1	First-line treatment for acute migraine attacks
8.2.1	Cytotoxic medicines	arsenic trioxide	Concentrate for solution for infusion	1 mg/ml, 2 mg/ml	C	Addition	1	1	2	Treatment of Acute promyelocytic leukaemia
8.2.1	Cytotoxic medicines	calcium folinate (calcium leucovorin)	Injection	10mg/ ml in 5 mL ampoule	C	Line Extension	1	1	1	Treatment of methotrexate toxicity

8.2.1	Cytotoxic medicines	dacarbazine	Powder for Injection	200 mg, 500 mg	C	Line Extension	1	1	2	Offer dosing flexibility
8.2.1	Cytotoxic medicines	doxorubicin (as pegylated liposomal)	Injection	2 mg/ml	C	Line Extension	1	1	2	Treatment of Kaposi sarcoma
8.2.1	Cytotoxic medicines	irinotecan	Injection	40 mg/2 ml, 100 mg/5 ml, 500 mg/25 ml	C	Addition	1	1	3	Treatment of metastatic colorectal cancer, nephroblastoma, and rhabdomyosarcoma
8.2.1	Cytotoxic medicines	oxaliplatin	Injection	50 mg/10 ml	C	Addition	1	1	1	Treatment of early stage colon cancer and metastatic colorectal cancer
8.2.1	Cytotoxic medicines	paclitaxel	Injection	6 mg/ml	C	Line Extension	1	1	2	Offer dosing flexibility, practical dosing
8.2.2	Targeted therapies	bortezomib	Powder for injection	2 mg, 3.5 mg	C	Addition	1	1	2	Treatment of multiple myeloma
8.2.2	Targeted therapies	dasatinib	Tablet	20, 50, 70 mg	C	Addition	1	1	3	Treatment of Imatinib-resistant chronic myeloid leukaemia
8.2.2	Targeted therapies	rituximab	Injection	10 mg/ml	C	Addition	1	1	2	Treatment of lymphomas and lymphocytic leukaemia
8.2.3	Immunomodulators	pembrolizumab	Concentrate for solution for infusion	25 mg/mL in 4 mL vial	C	Addition	1	1	1	Treatment of metastatic cervical and colorectal cancer
8.2.3	Immunomodulators	thalidomide	Capsule	50 mg	C	Addition	1	1	1	Treatment of multiple myeloma
8.2.4	Hormones and antihormones	abiraterone	Tablet	250 mg; 500 mg	C	Addition	1	1	2	Treatment of metastatic castration-resistant prostate cancer

8.2.4	Hormones and antihormones	tamoxifen	Tablet	10 mg	C	Line Extension	1	1	1	Offer dosing flexibility
8.2.5	Supportive medicines	allopurinol	Powder for injection	500 mg (as sodium)	C	Line Extension	1	1	1	Treatment of Tumour lysis syndrome
9	Therapeutic products to treat malnutrition disorders	f 75 therapeutic milk	Powder	Energy density:75 kcal/100 ml.	M	Addition	1	1	1	Address national nutrition program requirements
9	Therapeutic products to treat malnutrition disorders	f 100 therapeutic milk	Powder	Energy density:100 kcal/100 ml.	M	Addition	1	1	1	Address national nutrition program requirements
9	Therapeutic products to treat malnutrition disorders	ready to use therapeutic products	Sachet	500 Kcal	M	Addition	1	1	1	Address national nutrition program requirements
10.1	Antianaemia medicines	erythropoietin (epo)	Injection	2000 IU, 4000 IU	C	Addition	1	1	2	Used in anemia, chronic kidney disease and chemotherapy patients
10.1	Antianaemia medicines	folic acid	Oral liquid	1 mg/ml [c]		Line Extension	1	1	1	New oral liquid dosage form specific for children.
10.1	Antianaemia medicines	iron dextran	Injection	50 mg/ml	M	Deletion	1	1	1	Replaced by iron sucrose
10.1	Antianaemia medicines	iron sucrose	Injection	20 mg/ml	M	Addition	1	1	1	Better alternative to iron dextran
10.2	Medicines affecting coagulation	apixaban	Tablet	2.5 mg, 5 mg	M	Addition	1	1	2	A favorable safety profile compared to warfarin, thus improving patient adherence

10.2	Medicines affecting coagulation	phytomenadione	Tablet	5mg	M	Modification	1	1	1	Drug strength changed in line with WHO EML and clinical needs from 10 mg tablet to 5 mg
12.1	Antianginal medicines	glyceryl trinitrate	Injection	5ml	M	Line Extension	1	1	1	Critical medication for cardiovascular emergencies
12.1	Antianginal medicines	metoprolol succinate	Extended Release Tablet	25 mg, 50 mg, 100 mg	M	Line Extension	1	1	3	Improves patient adherence
12.3	Antihypertensive medicines	clonidine	Tablet	200 mcg	C	Addition	1	1	1	Essential for hypertension management in End-Stage Kidney Disease
12.4	Medicines used in heart failure	digoxin	Tablet	62.5 mcg	M	Line Deletion	1	1	1	Limited clinical utility
12.4	Medicines used in heart failure	spironolactone	Tablet	12.5 mg	M	Line Deletion	1	1	1	Limited clinical utility
12.5	Antithrombotic medicines	streptokinase	Injection:	750 000 IU, 1500 000 IU	C	Deletion	1	1	2	Use drastically decreased in favor of newer and safer alternative tenecteplase
12.5	Antithrombotic medicines	tenecteplase	Powder for injection	20 mg, 40 mg	C	Addition	1	1	2	Use case drastically increased in place of Streptokinase
12.6	Lipid lowering agent	fenofibrate	Tablet	80 mg	M	Line Deletion	1	1	1	Limited clinical utility
13.4	Medicines affecting skin differentiation and proliferation	fluorouracil	Ointment	0.05 %	C	Line Extension	1	1	1	Treatment of multiple actinic keratoses & superficial basal cell carcinoma

13.6	Humectants	glycerol	Solution	15-20%	M	Addition	1	1	1	Created a sub-section in line with WHO EML to address dermatological needs
13.6	Humectants	urea	Cream	0.05	C	Addition	1	1	1	Created a sub-section in line with WHO EML to address dermatological needs
15.2	Disinfectants	hypochlorous acid	Solution	≥ 150 parts per million	M	Addition	1	1	1	Created a sub-section in line with WHO EML to address disinfection needs in hospital settings
17.1	Antacids and antiulcer medicines	pantoprazole	Injection	40 mg	C	Addition	1	1	1	Standard of care for upper GI bleeding
17.2	Antiemetic medicines	aprepitant	capsule; Powder for oral suspension	80 mg, 125 mg, 165 mg; 125 mg	C	Addition	1	2	4	Essential for cancer care, reduces hospitalizations due to chemotherapy induced nausea and vomiting
17.2	Antiemetic medicines	promethazine	Injection; Oral liquid; Tablet	25 mg/ ml; 5 mg/ 5 ml;25 mg	M	Deletion	1	3	3	Safer alternatives available
17.6	Antispasmodic medicines	hyoscine hydrobromide	Injection	400 mcg/ ml, 600 mcg/ ml	C	Deletion	1	1	2	No molecule registered in Nepal, less sedating butylbromide listed in NLEM
18.1	Adrenal hormones and synthetic substitutes	prednisolone	Syrup	5 mg/5ml	M	Line Extension	1	1	1	Offer dosing flexibility, coverage of pediatric population
18.5.2	Oral hypoglycemic agent	dapagliflozin	Tablet	5mg, 10 mg	M	Addition	1	1	2	Multiple cardiovascular and renal benefits beyond glycemic control

18.5.2	Oral hypoglycemic agent	metformin	Tablet	SR 1 g	M	Line Extension	1	1	1	Convenient dosing and reduced gastro-intestinal irritation
18.5.2	Oral hypoglycemic agent	semaglutide	Injection solution	0.68 mg/ml; 1.34 mg/ml	C	Addition	1	1	2	Added as per need to address burden of diabetes and obesity
18.6	Thyroid hormones and antithyroid medicines	propylthiouracil	Tablet	50 mg	C	Addition	1	1	1	For use when alternative first-line treatment is not appropriate or available
18.7	Posterior pituitary hormone	desmopressin	Nasal spray	150 mcg /metered spray	M	Modification	1	1	1	Strength of the nasal spray changed in line with WHO EML
18.8	Medicines for disorders of the pituitary hormone system	octreotide	Injection	100 mcg	C	Addition	1	1	1	A rapid, accessible, and effective treatmetnt for upper GI bleeding
19.2	Sera and immunoglobulins	equine rabies immunoglobulin (erig)	Injection	200 IU/ml or 300 IU/ml	M	Addition	1	1	1	Affordable rabies immunoglobulin
20	Muscle relaxants (peripherally acting) and cholinesterase inhibitors)	pyridostigmine	Tablets	60 mg; 180 mg XR	C	Addition	1	1	2	Standard treatment for myasthenia gravis
21.1	Anti-inflammatory agents	flurbiprofen	Eye Drops	0.3% w/v	C	Addition	1	1	1	Essential for modern cataract surgery procedures
21.4	Miotics and antiglaucoma medicines	latanoprost	Eye drops	0.005%	C	Addition	1	1	1	Highly effective, safe treatment in glaucoma
22.3	Uterotonics	carbetocin	Injection	100 mcg/ml	C	Addition	1	1	1	Alternative to oxytocin in high-risk obstetric cases, heat stable

22.4	Medicines for medical abortion	mifepristone + misoprostol	Tablet	200mg + 200 mg	M	Modification	1	1	1	Shifted from complementary to core list with introduction of new sub0section in WHO EML
22.4	Medicines for medical abortion	misoprostol	Tablet	200 mg, 600 mg	M	Modification	1	1	2	Shifted from complementary to core list with introduction of new sub0section in WHO EML
22.5	Other medicines administered to the mother	multiple micronutrient supplementatio n	Tablet	Multiple Components	M	Addition	Multiple	1	1	Address requirement of national nutrition program
22.6	Medicines administered to the neonate	prostaglandin E1	Solution for injection	0.5 mg/ml in alcohol	C	Addition	1	1	1	Life saving molecule for patent ductus arteriosus
24.1	Medicines used in psychotic disorders	olanzapine	Powder for Injection	10 mg	M	Line Extension	1	1	1	Alternative route when oral administration not feasible
24.1	Medicines used in psychotic disorders	risperidone	Solid oral dosage form	0.25 mg, 0.5 mg, 3 mg	M	Line Extension	1	1	3	Offer dosing flexibility
24.2.1	Medicines used in depressive disorders	escitalopram	Solid oral dosage form	10 mg	C	Addition	1	1	1	Better efficacy and tolerability
24.3	Medicines used in generalized anxiety and sleep disorders	clonazepam	Tablet	0.25 mg, 1 mg, 2 mg	M	Addition	1	1	3	Well-established safety and efficacy profile

24.3	Medicines used in generalized anxiety and sleep disorders	lorazepam	Injection	4 mg/ml	M	Line Extension	1	1	1	Preferred benzodiazepine for status epilepticus and sedation
24.3	Medicines used in generalized anxiety and sleep disorders	propranolol	Tablet	10 mg	M	Line Extension	1	1	1	Lower strength preferred in anxiety for children and dose-sensitive adults
24.5	Medicines used in disorders due to psychoactive substance use	acamprosate calcium	Tablet	333 mg	M	Addition	1	1	1	Maintenance of abstinence in patients with alcohol use disorder
24.5	Medicines used in disorders due to psychoactive substance use	chlordiazepoxide	Tablet	10 mg, 25 mg	M	Modification	1	1	2	Used for alcohol withdrawal syndrome management
24.5	Medicines used in disorders due to psychoactive substance use	disulfiram	Tablet	200 mg	M	Deletion	1	1	1	Safer alternatives available
25.1	Antiasthmatic and medicines for chronic obstructive pulmonary disease	aminophylline	Injection	25 mg/ ml	M	Deletion	1	1	1	Limited clinical utility

25.1	Antiasthmatic and medicines for chronic obstructive pulmonary disease	budesonide (a) & formoterol(b)	Dry powder inhaler	100 mcg (A) + 6 mcg (B), Inhalation 200 mcg (A)+ 2 mcg(B)	M	Addition	2	1	2	Managment of asthma and COPD
25.1	Antiasthmatic and medicines for chronic obstructive pulmonary disease	salbutamol	Injection	500 mcg / ml in 1ml, 5 ml ampoule	M	Modification	1	1	1	Updated strength of injection in line with WHO EML
27	Vitamins and minerals	multiple micronutrient powder	Sachets	Multiple Components	M	Addition	Multiple	1	1	Address requirement of national nutrition program
27	Vitamins and minerals	retinol	Tablets (sugar coated)	10000 IU	M	Line Deletion	1	1	1	Deleted the dosage form in line in WHO EML, based on use case scenario
27	Vitamins and minerals	sodium bicarbonate	Tablet	500 mg, 1 g	M	Line Extension	1	1	2	Essential treatment for severe metabolic acidosis
28	Ear, nose and throat medicines	acetic acid	Topical solution	2% in alcohol	M	Addition	1	1	1	Essential to treat otitis externa. To decrease antibiotic overuse
28	Ear, nose and throat medicines	mometasone furoate	Nasal spray (aqueous)	50 mcg per spray	M	Addition	1	1	1	Essential to treat and prevent symptoms associated with allergic rhinitis
30	Dental medicines and preparations	fluoride	Varnish	22,500 ppm	M	Addition	1	1	1	Essential for dental caries prevention
30	Dental medicines and preparations	lignocaine	Injection Spray Topical(sterile)	1%, 2% (hydrochloride) in vial 5-10% 2% w/w	M	Line Extension	1	1	1	Pain free analgesia in dentistry used prior to injections

30	Dental medicines and preparations	benzocaine	Ointment Solution	0.2% 20%	M	Modification	1	2	2	Shifted from Section 28 to Section 30 in line with WHO EML developing a new section
30	Dental medicines and preparations	chlorhexidine	Solution	0.2% (gluconate)	M	Modification	1	1	1	Shifted from Section 28 to Section 30 in line with WHO EML developing a new section
30	Dental medicines and preparations	lidocaine (lignocaine) + epinephrine (adrenaline)	Injection	2% (as hydrochloride or sulfate) + epinephrine 1: 200 000 in vial	M	Modification	2	1	1	Shifted from Section 28 to Section 30 in line with WHO EML developing a new section
30	Dental medicines and preparations	zinc oxide	Powder		M	Modification	1	1	1	Shifted from Section 28 to Section 30 in line with WHO EML developing a new section

ANNEX II

Medicines with age or weight restrictions

artemether + lumefantrine	> 5 kg weight
atazanavir + ritonavir	≥3 months and ≥5 kg
atropine	>3 months
benzyl benzoate	> 2 years
betamethasone topical preparations	hydrocortisone preferred in neonates
cefazolin	> 1 month (neonatal use is limited and dosing/PK differs)
ceftriaxone	> 41 weeks corrected gestational age
darunavir	> 3 years
dapagliflozin	>10 years (Safety not established in children below 10 years)
dolutegravir	≥ 4 weeks and ≥ 3 kg (10 mg dispersible tablet) ≥ 25 kg (50 mg tablet)
doxycycline	> 8 years (except for serious infections e.g. cholera when no alternative exists)
fluoxetine	> 8 years
ibuprofen	>3 months (except IV form for patent ductus arteriosus)
loperamide	> 2 years; aged 2-12 years carefully consider drug effects
mefloquine	>5 kg or >3 months
metoclopramide	Not in neonates
nevirapine	> 6 weeks (except when used for neonatal prophylaxis)
ondansetron	> 1 month
primaquine	> 6 months
propylthiouracil	> 6 years
silver sulfadiazine	> 2 months
tetracaine	Not in preterm neonates

ANNEX III

Explanation of dosage forms

A. Principal dosage forms used in EML - oral administration

Term	Definition
Solid oral dosage form	Refers to tablets or capsules or other solid dosage forms such as 'melts' that are immediate-release preparations. The term 'solid oral dosage form' is never intended to allow any type of modified-release tablet
Tablets	Refers to: • uncoated or coated (film-coated or sugar-coated) tablets that are intended to be swallowed whole • unscored and scored (Scored tablets may be divided for ease of swallowing, provided that the dose is a whole number of tablets) • tablets that are intended to be chewed before being swallowed • tablets that are intended to be dispersed or dissolved in water or another suitable liquid before being swallowed • tablets that are intended to be crushed before being swallowed The term 'tablet' without qualification is never intended to allow any type of modified-release tablet.
Tablets (qualified)	Refers to a specific type of tablet: • chewable - tablets that are intended to be chewed before being swallowed dispersible - tablets that are intended to be dispersed in water or another suitable liquid before being swallowed soluble - tablets that are intended to be dissolved in water or another suitable liquid before being swallowed • crushable - tablets that are intended to be crushed before being swallowed • scored - tablets bearing a break mark or marks where sub-division is intended in order to provide doses of less than one tablet • sublingual - tablets that are intended to be placed beneath the tongue. The term 'tablet' is always qualified with an additional term (in parentheses) in entries where one of the following types of tablet is intended: gastroresistant (such tablets may sometimes be described as enteric-coated or as delayed-release), prolonged release or another modified-release form.

Capsules	Refers to hard or soft capsules. The term 'capsule' without qualification is never intended to allow any type of modified release capsule.
Capsules (qualified)	The term 'capsule' with qualification refers to gastro-resistant (such capsules may sometimes be described as enteric-coated or as delayed-release), prolonged-release or another modified-release form.
Term	**Definition**
Granules	Preparations that are issued to patient as granules to be swallowed without further preparation, to be chewed, or to be taken in or with water or another suitable liquid. The term 'granules' without further qualification is never intended to allow any type of modified-release granules.
Oral powder	Preparations that are issued to patient as powder (usually as single dose) to be taken in or with water or another suitable liquid.
Oral liquid	Liquid preparations intended to be swallowed i.e. oral solutions, suspensions, emulsions and oral drops, including those constituted from powders or granules, but not those preparations intended for oromucosal administration e.g. gargles and mouthwashes. Oral liquids presented as powders or granules may offer benefits in the form of better stability and lower transport costs. If more than one type of oral liquid is available on the same market (e.g. solution, suspension, granules for reconstitution), they may be interchanged. It is preferable that oral liquids do not contain sugar and that solutions for children do not contain alcohol.

B. Principal dosage forms used in EML – parenteral administration

Term	Definition
Injection	Refers to solutions, suspensions and emulsions including those constituted from powders or concentrated solutions.
Injection (qualified)	Route of administration is indicated in parentheses where relevant.
Injection (oily)	The term `injection' is qualified by `(oily)' in relevant entries
Intravenous infusion	Refers to solutions and emulsions including those constituted from powders or concentrated solutions

C. Other dosage forms

Term	Definition
Mode of administration	Term to be used
To the eye	Eye drops, eye ointments…
Topical	For liquids: lotions, paints For semi-solids: cream, ointment
Rectal	Suppositories, gel or solution.
Vaginal	Pessaries or vaginal tablets
Inhalation	Powder for inhalation, pressurized inhalation, nebulizer

Annex IV

Consulted Experts

S. N.	Name of the Experts	Designation	Organization
1.	Mr. Bharat Bhattarai	Director General	Department of Drug Administration, MoHFS
2.	Mr. Narayan Prasad Dhakal	Chief Drug Administrator	MOHFS
3.	Mrs. Shiwani Khadgi	Senior Drug Administrator	Department of Drug Administration, MoHFS
4.	Dr. Pawan Jung Rayamajhi	Director	Managament Division, MoHFS
5.	Dr. Saroj Sharma	Chief	Quality Assurance and Regulation Division (QSRD), MoHFS
6.	Dr. Bibek Kumar Lal	Chief	Family Welfare Division, MoHFS
7.	Mr. Gajendra Bahadur Bhuju	Former Director General	Professor, CIST College
8.	Mr. Radha Raman Prasad	Former Director General	Department of Drug Administration
9.	Mr. Pramod KC	Former Senior Drug Administrator	Department of Drug Administration, MoHFS
10.	Mr. Kiran Sunder Bajracharya	Senior Drug Administrator	Department of Drug Administration, MoHFS
11.	Ms. Binala Joshi	Pharmacy Officer	Department of Drug Administration, MoHFS
12.	Mr. Umanga Tripathi	Pharmacy Officer	Department of Drug Administration, MoHFS
13.	Mr. Mukendra Panjiyar	Pharmacy Officer	Department of Drug Administration, MoHFS
14.	Ms. Renu Poudel	Pharmacy Supervisor	Department of Drug Administration, MoHFS
15.	Dr Gampo Dorji	Senior Health Policy Advisor, HSP	WHO NEPAL
16.	Mrs. Sushma Shakya	Drug and Medical Product Officer, HSP	WHO NEPAL
17.	Dr Kenza Bennani	Technical Officer, DPC	WHO NEPAL
18.	Dr Hiroshi Azuma	Technical Officer, MH	WHO NEPAL
19.	Dr Subash Lakhe	NPO, DPC	WHO NEPAL
20.	Dr Kedar Marhatta	NPO, MH	WHO NEPAL
21.	Mr. Raj N. Mandal	Program Director	Helen Keller International

22.	Ms. Pooja Pandey Rana		Helen Keller International
23.	Ms. Sasmita Poudel		Helen Keller International
24.	Mr. Bhogendra Raj Dotel	Public Health Expert	
25.	Mr. Lila Bikram Thapa Chhetri		Family Welfare Division, MoHFS
26.	Dr. Gauri Pradhan Shrestha		Family Welfare Division, MoHFS
27.	Mr. Kamlesh Kumar Mishra		Department of Health Services
28.	Dr. Fanindra Prasad Baral		Department of Health Services
29.	Mr. Sanjeev Sharma Kattel	Pharmacist	Department of Health Services
30.	Dr. Anil Bikram Karki	President	Nepal Medical Association
31.	Dr. Pradeep Bhandari	General Secretary	Nepal Dental Association (NDA)
32.	Prof. Dr. Ratna Mani Gajurel	President	Nepalese Cardiac Society, Society of Internal Medicine of Nepal (SIMON)
33.	Dr. Dipankar Prajapati	General Secretary	Nepalese Cardiac Society
34.	Dr. Ramila Shrestha	General Secretary	Society of Internal Medicine of Nepal (SIMON)
35.	Prof. Dr. Padam Raj Pant	President	Nepal Society of Obstetricians and Gynaecologists (NESOG)
36.	Prof. Dr. Bimal Kumar Pandey	President	Nepal Orthopaedic Association (NOA)
37.	Prof. Dr. Arun Neupane	President	Nepal Paediatric Society (NEPAS)
38.	Dr. Santosh Adhikari	Consultant Pediatrician	Nepal Paediatric Society (NEPAS)
39.	Dr. Pushpa Mani Kharal	President	General Practice Association of Nepal (GPAN)
40.	Dr. Bishwa Dawadi	General Secretary	General Practice Association of Nepal (GPAN)
41.	Dr. Anil Shrestha	President	Nepal Association of Urological Surgeons (NAUS)
42.	Dr. Tejsu Singh Malla	General Secretary	Nepal Ophthalmic Society (NOS)
43.	Dr. Dhiraj Narayan Manandhar	General Secretary	Nepal Society of Nephrology (NSN)
44.	Dr. Rabi Ram Shrestha	President	Nepalese Society of Critical Care Medicine (NSCCM)
45.	Dr. Ankit Rimal	General Secretary	Nepalese Society of Critical Care Medicine (NSCCM)
46.	Dr. Santosh Acharya	Consultant Critical Care Specialist	Nepalese Society of Critical Care Medicine (NSCCM)

47.	Dr. Bhupendra B. Basnet	General Secretary	Nepalese Society of Gastroenterologists
48.	Dr. Rabi Shakya	President	Psychiatrists Association of Nepal (PAN)
49.	Dr. Manoj Dhungana	General Secretary	Psychiatrists Association of Nepal (PAN)
50.	Dr. Anil Shrestha	President	Society of Anaesthesiologists of Nepal (SAN)
51.	Dr. Manisha Singh	President	Society of Dermatologists, Venereologists and Leprologists of Nepal (SODVELON)
52.	Dr. Bikash Poudel	Consultant Dermatologist	Society of Dermatologists, Venereologists and Leprologists of Nepal (SODVELON)
53.	Dr. Rabindra B. Pradhananga	President	Society of Otolaryngologists of Nepal (SOL Nepal)
54.	Dr. Dipesh Shakya	General Secretary	Society of Otolaryngologists of Nepal (SOL Nepal)
55.	Dr. Sangya Poudel	Consultant Otorhinolaryngologist	Society of Otolaryngologists of Nepal (SOL Nepal)
56.	Dr. Sanjeet Krishna Shrestha	General Secretary	Nepalese Respiratory Society
57.	Dr. Brajendra Srivastava	Consultant Pulmonologist	Nepalese Respiratory Society
58.	Dr. Ravi Mahat	Consultant Pulmonologist	Grande International Hospital
59.	Dr. Ghanshyam Kharel	Consultant Neurologist	Bansbari Neuro Hospital, Kathmandu
60.	Dr. Lekh Jung Thapa	Consultant Neurologist	National Neuro Center, Maharajgunj
61.	Dr. Pawana Kayastha	Consultant Paediatrician	Kathmandu Medical College, Sinamangal
62.	Dr. Sandhya Chapagain	President	Nepal Cancer Society
63.	Dr. Sudeep Shrestha	Consultant Oncologist	Medical Oncologist, Nepal Cancer Hospital and Research Center
64.	Mr. Anish Shrestha	Publicity Secretary	Nepal Pharmceutial Assocation
65.	Mr. Sanjiv Kumar Pandey	Registrar	Nepal Pharmacy Council
66.	Dr. Sunil Shrestha	Clinical Pharmacist	Kathmandu Cancer Center, Tathali
67.	Dr. Ghulam Khan	Pharmacy Academician	Pokhara University
68.	Dr. Jyoti Bhattarai	Consultant Endocrinologist	Metro Kathmandu Hospital

69.	Dr. Prenit Pokhrel	Dentist, Oral and Maxillofacial surgeon	Karnali Academy of Health Sciences (Dean)
70.	Dr. Retu Amatya	Consultant Microbiologist	FHI 360
71.	Dr. Dina Shrestha	Consultant Endocrinologist	Norvic Hospital, Thapathali
72.	Dr. Anup Subedi	Infectious Disease Expert	Burn Hospital, Kirtipur
73.	Dr. Prabhat Adhikari	Infectious Disease Expert	CAMS, Baneshwor
74.	Dr. Dinesh Koirala	Consultant Gastroenterologist	MMC-TUTH, IOM
75.	Dr. Akriti Pokharel	Consultant Pharmacologist	MMC-TUTH, IOM
76.	Ms. Sushma Acharya	Pharmacist	BPKMCH
77.	Mr. Kabin Malekhu	Pharmacist	PhAN
78.	Mr. Amrit Bista		Mauri Ventures
79.	Dr. Ramesh Sharma Poudel	Pharmacist	Chief, Medicines and Health Technological Sub-committee, Ministry of Health and Population
80.	Dr. Shivaji Poudel	Onco-Radiologist	BPKMCH, Chitwan

ANNEX V

Medicine Inclusion request for amendment of NLEM

S. No.	Medicine Name & Details	Society
1	5-Fluorouracil (5-FU): Topical Cream: 5%; Injection: 250 mg/5 mL, 500 mg/10 mL	Dermatology Society
2	Abiraterone: Tablet: 250 mg, 500 mg	Oncology Consultant-Medical Oncologist
3	Acarbose: Tablet: 25 mg, 50 mg	Endocrine Society
4	Aceclofenac: Tablet: 100 mg	Nepal Orthopedic Association
5	Acetazolamide: Tablet	Internal Medicine
6	Acetic Acid: Topical Solution: 2% in alcohol	ENT Society
7	Adalimumab: Prefilled Syringe/Auto-injector (Subcutaneous): 40 mg/0.8 mL	Dermatology Society
8	Adenosine: Injection: 3 mg/mL (2 mL)	Cardiology Society
9	Alteplase: Powder for Injection: 10 mg, 20 mg, 50 mg	Neuro Consultant-Bansbari Neuro Hosp & National N H
10	Amino Acids: Infusion: 10% (100 mL)	Paed Society
11	Amino Acids: Infusion: 10% (100 mL)	Paropakar Maternity and Women's Hospital
12	Amitriptyline: Tablet: 10 mg, 25 mg, 75 mg	Neuro Consultant-Bansbari Neuro Hosp & National N H
13	Amphotericin B Deoxycholate: Injection	Paropakar Maternity and Women's Hospital
14	Amphotericin B Lipid Complex: Injection	Infectious Disease Consultant
15	Amphotericin B Liposomal: Injection	Infectious Disease Consultant
16	Antithymocyte Globulin: Injection	ENT Society
17	Antivenom Immunoglobulin: Injection	Infectious Disease Consultant
18	Apixaban: Tablet: 2.5 mg, 5 mg	Cardiology Society
19	Arsenic Trioxide: Solution for Infusion: 1 mg/mL, 2 mg/mL; Injection: 10 mg/mL	Oncology Consultant-Medical Oncologist
20	Atorvastatin-40/ Rosuvastatin 20	Cardiology Consultant-KMC
21	Azacitidine: Tablet: 100 mg	Oncology society
22	Aztreonam: Injection	Internal Medicine
23	Baclofen: Tablet	Pharmacist
24	Betahistine: Tablet: 8 mg, 16 mg, 24 mg	Nepal Orthopedic Association
25	Betaxolol: Eye Drops	Ophthalmology Society

26	Bortezomib: Powder for Injection: 3.5 mg	Oncology Consultant-Medical Oncologist
27	Bosentan + Sildenafil	Cardiology Consultant- KMC
28	Bosentan: Tablet: 62.5 mg, 125 mg	Cardiology Society
29	Budesonide + Formoterol: Inhalation: 200 mcg/6 mcg, 400 mcg/12 mcg	Nepal Respiratory Society
30	Budesonide: Nebulizer Suspension: 0.5 mg, 1 mg	Nepal Respiratory Society
31	Buprenorphine: Sublingual Tablet: 200 mcg, 400 mcg; Transdermal Patch: 5 mcg/hr, 10 mcg/hr	Cancer pain Consultant-Clincal Pharmacist
32	Bupropion: Tablet	From Pharmacist
33	Caffeine Citrate: Injection: 20 mg/mL	Paropakar Maternity and Women's Hospital
34	Calcitriol/Alfacalcidol: Capsule: 0.25 mcg	Paed Society
35	Calcium Acetate: Tablet: 667 mg	Nephro Society
36	Calcium Carbonate: Oral Liquid	Nephro Society
37	Calcium Chloride: Injection: 10%, 1 g/10 mL	Critical Care Society
38	Cangrelor: Injection	Neurointerventionist Consultant-Bansbari Neuro Hosp
39	Carbetocin: Injection: 100 mcg/mL	Gynecology Society
40	Caspofungin: Injection	Infectious Disease Consultant
41	Cefazolin: Injection	Infectious Disease Consultant
42	Cefepime: Injection	Infectious Disease Consultant
43	Ceftazidime + Avibactam: Injection: 2 g/500 mg	Urology Society
44	Ceftazidime: Injection: 250 mg, 500 mg, 1 g, 2 g	NATG Society
45	Ceftriaxone: Injection	Infectious Disease Consultant
46	Celecoxib: Tablet	Oncology society
47	Chloramphenicol + Dexamethasone: Ear Drops: 5% + 0.1%	ENT Society
48	Chloramphenicol + Dexamethasone: Eye Drops	Ophthalmology Consultant-KMC
49	Chlorhexidine Gluconate: Mouthwash: 0.2%	Dental Society
50	Chlorthalidone: Tablet	Internal Medicine

51	Chlorzoxazone + Paracetamol: Tablet	Nepal Orthopedic Association
52	Chlorzoxazone: Tablet	
53	Cholera Vaccine: Oral/Injection	Infectious Disease Consultant
54	Cilnidipine: Tablet: 5 mg, 10 mg, 20 mg	Cardiology Society
55	Cinnarizine: Tablet: 25 mg, 75 mg	Nepal Orthopedic Association
56	Ciprofloxacin + Dexamethasone: Ear Drops: 3% + 0.1%	ENT Society
57	Clonazepam: Tablet: 0.25 mg	Psychiatry Society
58	Clonidine: Tablet	Nephro Society
59	Clonidine: Transdermal Patch	
60	CMC Sodium: Eye Drops: 0.5%, 1%	Ophthalmology Consultant-Assos.
61	Colchicine: Tablet	*From Pharmacist
62	Crystalline Penicillin: Injection	Paropakar Maternity and Women's Hospital
63	Cyclosporine: Eye Drops	Ophthalmology Society
64	Cyclosporine: Oral Suspension	Internal Medicine
65	Dabigatran: Tablet: 75 mg, 110 mg, 150 mg	Cardiology Society
66	Dantrolene: Capsule	Anesthesia Society
67	Dapagliflozin 5 mg,10 mg	Endocrine Society
68	Dapagliflozin 5 mg,10 mg	Nephro Society
69	Dapagliflozin: Tablet: 5 mg, 10 mg	Cardiology Society
70	Darbepoetin: Injection	Internal Medicine
71	Dasatinib: Tablet: 20 mg, 50 mg, 70 mg, 100 mg, 140 mg	Oncology Consultant-Medical Oncologist
72	Decitabine: Injection: 50 mg	TUTH
73	Degarelix: Injection: 80 mg	Urology Society
74	Dehydroepiandrosterone (DHEA): Tablet: 75 mg	Gynecology Society
75	Dengue Vaccine: Injection	Infectious Disease Consultant
76	Denosumab: Injection: 60 mg, 120 mg	Oncology Society
77	Desmopressin: Tablet: 0.1 mg, 0.2 mg; Nasal Spray	Paed Society
78	Desmopression oral	Endocriology Consultant-Consultant Endocrinologist
79	Dexamethasone: Injection: 4 mg/mL; Tablet: 0.5 mg, 4 mg	Cancer pain Consultant-Clinical Pharmacist
80	Dextranomer Microspheres: Injection: 50 mg/mL	Urologists Society

81	Diethylcarbamazine: Tablet	Infectious Disease Consultant
82	Digoxin: Syrup (Oral): 0.05 mg/mL; Injection	Paropakar Maternity and Women's Hospital
83	Diloxanide: Tablet	Infectious Disease Consultant
84	Diltiazem: Tablet	Internal Medicine
85	Dorzolamide + Timolol: Eye Drops	Ophthalmology Society
86	Dorzolamide: Eye Drops	Ophthalmology Society
87	Doxofylline: Tablet	Internal Medicine
88	Doxorubicin Liposomal: Injection: 50 mg	Oncology Society
89	Empagliflozin: Tablet: 10 mg, 25 mg	Endocrine Society
90	Empagliflozin/Dapagliflozin	Cardiology Consultant- KMC
91	Emtricitabine + Tenofovir: Tablet	Infectious Disease Consultant
92	Erlotinib: Tablet: 100 mg, 150 mg	Oncology Consultant-Medical Oncologist
93	Erythropoietin (EPO): Injection: 4000 U, 6000 U	Nephro Society
94	Escitalopram: Tablet	Psychiatry Consultant- KMC
95	Esomeprazole Bicarbonate: Tablet	Internal Medicine
96	Ethambutol: Tablet	Infectious Disease Consultant
97	Etoricoxib: Tablet	From Pharmacist
98	F 100: Nutritional Formula	Family Welfare Division
99	F 75: Nutritional Formula	Family Welfare Division
100	Faropenem: Tablet	Internal Medicine
101	FDCs in cardiovascular medicine	Cardiology Society
102	Febuxostat: Tablet	Internal Medicine
103	Fentanyl: Transdermal Patch	From Pharmacist
104	Fibrin Glue	Ophthalmology Society
105	Fibrinogen (Human Plasma-Derived): Injection: 1 g	Critical Care Society
106	Finerenone: Tablet	Internal Medicine
107	Fludarabine: Injection: 50 mg	Oncology Society
108	Fludrocortisone: Tablet	Pharmacist
109	Fluorescein Dye: Injection	Ophthalmology Society
110	Fluoride Varnish: Topical Application: 5%	Dental Society
111	Fluorometholone: Eye Drops	Ophthalmology Society
112	Fluphenazine: Injection	Psychiatry Consultant- KMC

113	Flurbiprofen: Eye Drops: 0.3% w/v	Ophthalmology Consultant-KMC
114	Fluticasone Propionate: Nasal Spray: 50 mcg/spray	ENT Society
115	Fluticasone: Inhalation: 50 micrograms	Nepal Respiratory Society
116	Fosfomycin: Sachet: 3 g; Injection: 2 g, 4g	Urology Society
117	Fulvestrant: Injection: 250 mg, 500 mg	Oncology Society
118	Gabapentin: Capsule: 300 mg, 400 mg; Tablet: 600 mg, 800 mg	Cancer pain Consultant-Clincal Pharmacist
119	Ganciclovir: Injection	Paropakar Maternity and Women's Hospital
120	Gargle: Solution	From Pharmacist
121	Glecaprevir + Pibrentasvir: Tablet	Infectious Disease Consultant
122	Glimepiride: Tablet: 1 mg, 2 mg	Endocrine Society
123	Glucose: Powder: 75 g	Endocrine Society
124	Granisetron: Tablet/Injection	Pain and Palliative Care Consultant-Assoc. Prof. PU
125	Granulocyte Colony-Stimulating Factor (GCF): Injection: 30 mcg	Oncology Society
126	Griseofulvin: Tablet	Infectious Disease Consultant
127	HBV Vaccine: Injection	NATG Society
128	Hepatitis B Immunoglobulin: Injection	NATG Society
129	Herpes Zoster Vaccine: Injection	Infectious Disease Consultant
130	HPMC (Hydroxypropyl Methylcellulose): Ointment	Ophthalmology Society
131	Human Milk Fortifier: Powder (Oral): 1 g	Paropakar Maternity and Women's Hospital
132	Hydralazine: Injection: 20 mg/mL	Critical Care Society
133	Hydrocortisone: Injection; Tablet: 10 mg, 20 mg	Endocrine Society
134	Hydromorphone: Injection: 1 mg/mL, 2 mg/mL	Critical Care Society
135	Hyoscine Butylbromide: Tablet: 10 mg; Injection: 20 mg/mL	Cancer pain Consultant-Clincal Pharmacist
136	Ifosfamide: Injection: 500 mg, 1 g, 2 g	Oncology Consultant-Medical Oncologist
137	Imipenem-Cilastatin: Injection	Infectious Disease Consultant
138	Imiquimod: Cream: 5%	Dermatology Society

139	Indomethacin: Tablet	
140	Insulin Glargine: Injection	Endocrine Society
141	Insulin Glargine: Injection	Endocriology Consultant-Consultant Endocrionlogist
142	Interferon Alpha 2b: Eye Drops	Ophthalmology Society
143	Irinotecan: Injection: 40 mg/2 mL, 100 mg/ 5 mL, 500 mg/25 mL	Oncology Consultant-Medical Oncologist
144	Iron Sucrose: Injection	Internal Medicine
145	Isoniazid: Tablet	Infectious Disease Consultant
146	Isosuprine: Injection: 10 mg/mL (4 mL)	Gynecology Society
147	Itopride: Tablet	Internal Medicine
148	Itraconazole: Eye Ointment	Ophthalmology Society
149	Japanese Encephalitis Vaccine: Injection	Infectious Disease Consultant
150	Ketorolac: Eye Drops	Ophthalmology Society
151	Lactulose: Syrup	Pain and Palliative Care Consultant-Assoc. Prof. PU
152	Lamotrigine: Tablet: 25 mg, 50 mg, 100 mg, 200 mg; Chewable/Dispersible Tablet: 2 mg, 5 mg, 25 mg, 50 mg, 100 mg, 200 mg	Neuro Consultant-National Neuro Hospital
153	Latanoprost: Eye Drops: 50 micrograms/mL	Ophthalmology Society
154	Lenvatinib: Tablet: 4 mg, 8 mg	
155	Letrozole: Tablet: 1 mg	Oncology Consultant-Medical Oncologist
156	Leuprorelin: Injection: 7.5 mg, 22.5 mg	Oncology Consultant-Medical Oncologist
157	Levetiracetam: Oral Solution: 100 mg/mL; Tablet: 250 mg, 500 mg, 750 mg, 1000 mg	Neuro Consultant-National Neuro Hospital
158	Levosalbutamol: Inhalation Suspension	Nepal Respiratory Society
159	Lidocaine with Adrenaline: Injection: 1:100,000, 1:80,000	Dentistry Consultant-Associate Prof
160	Lidocaine: Spray: 4%, 5-10%	Dentistry Consultant-Associate Prof
161	Linagliptin: Tablet: 5 mg	Endocrine Society
162	Lipid: Infusion: 20% (100 mL)	Paropakar Maternity and Women's Hospital
163	Lipiodol (Ethiodized Oil): Injection	Radiology Society
164	Loperamide: Tablet: 2 mg	From Consultant

165	Loratadine: Tablet	Consultant
166	Lorazepam: Injection: 4 mg/mL	Critical Care Society
167	Loteprednol Etabonate: Eye Drops	Ophthalmology Society
168	Magnesium: Oral Preparation	Internal Medicine
169	MCT Oil: Oral	Paropakar Maternity and Women's Hospital
170	Measles-Mumps-Rubella (MMR) Vaccine: Injection	Infectious Disease Consultant
171	Mebeverine: Tablet	Internal Medicine
172	Mesalamine: Tablet: 400 mg	From TUTH
173	Metformin: Tablet: 500 mg, 850 mg; Sustained Release: 1 g	Endocrine Society
174	Methadone: Oral Liquid: 5 mg/mL; Tablet: 5 mg, 10 mg	Cancer pain Consultant-Clincal Pharmacist
175	Methylene Blue: Injection: 1%, 10 mg/mL	Critical Care Society
176	Metoclopramide: Tablet/Injection	Pain and Palliative Care Consultant-Assoc. Prof. PU
177	Metolazone: Tablet	Internal Medicine
178	Metoprolol Succinate Extended Release – 25 mg, 50 mg, and 100 mg	Cardiology Society
179	Metoprolol: Injection: 1 mg/mL (5 mL); Tablet (Extended Release): 25 mg, 50 mg, 100 mg	Cardiology Society
180	Micafungin: Injection	Infectious Disease Consultant
181	Midazolam: Injection	Neuro Consultant-Bansbari Neuro Hosp
182	Midodrine: Tablet: 2.5 mg, 5 mg	Critical Care Society
183	Minoxidil: Oral Tablet: 2.5 mg, 5 mg, 10 mg	Dermatology Society
184	Mitomycin C: Injection: 2 mg	Ophthalmology Society
185	MMS (Multiple Micronutrient Supplement)	Family Welfare Division
186	MNP (Micronutrient Powder): Powder	Family Welfare Division
187	Mometasone Furoate: Nasal Spray: 50 mcg/spray	ENT Society
188	Moxifloxacin: Eye Drops/Injection	Ophthalmology Consultant-Assos. Prof @ KMC

189	Multivitamin: Injection	Paropakar Maternity and Women's Hospital
190	Mycophenolate Mofetil Sodium: Tablet	Internal Medicine
191	Mycophenolate Mofetil: Tablet	Internal Medicine
192	Naltrexone: Tablet: 50 mg	Psychiatry Society
193	Naproxen: Tablet: 250 mg, 500 mg	Neuro Consultant-Bansbari Neuro Hosp
194	Nasal Saline: Solution	From Pharmacist
195	Netarsudil: Eye Drops	Ophthalmology Society
196	Nicotine: Transdermal Patch	From Pharmacist
197	Nimodipine: Injection	Neurointerventionist Consultant-Bansbari Neuro Hospital
198	Nitric Oxide/Nitrous Oxide: Gas	Cardiology Society
199	Nitroglycerin: Injection: 5 mg/mL; Sublingual Tablet	Cardiology Society
200	Nivolumab: Injection: 40 mg, 100 mg	Oncology Society
201	Nystatin: Tablet/Suspension	Infectious Disease Consultant
202	Octreotide: Injection: 50 mcg, 100 mcg	Gastroenterology Society
203	Ofloxacin: Eye Drops	Ophthalmology Consultant-Assos. Prof @ KMC
204	Olopatadine: Eye Drops: 0.2% w/v	Ophthalmology Society
205	Onabotulinumtoxin A: Injection: 100 units	Urologists Society
206	Onco BCG: Intravesical Therapy: 80 mg	Urology Society
207	Ondansetron: Tablet/Injection	Pain and Palliative Care Consultant-Assoc. Prof. PU
208	Osimertinib: Tablet: 80 mg	Onchology society
209	Oxaliplatin: Injection: 50 mg, 100 mg, 200 mg; Powder: 50 mg, 100 mg	Oncology Consultant-Medical Oncologist
210	Ozurdex (Dexamethasone): Intravitreal Implant	Ophthalmology Society
211	Palbociclib: Tablet: 100 mg, 125 mg	Oncology Society
212	Pantoprazole: Injection: 40 mg	TUTH
213	Pazopanib: Tablet: 200 mg, 400 mg	Oncology Society
214	Pegaspargase: Injection: 750 U/mL	Oncology Consultant-Medical Oncologist

215	Pegfilgrastim: Injection: 6 mg/0.6 mL	Oncology Consultant-Medical Oncologist
216	Pegylated Granulocyte Colony-Stimulating Factor (Peg GCF): Injection	Oncology Society
217	Pembrolizumab: Injection: 100 mg/4 mL	Urology Society
218	Pemetrexed: Injection: 100 mg, 500 mg	Oncology Society
219	Peritoneal Dialysis Solution: Solution	Internal Medicine
220	Permethrin: Cream/Lotion	Infectious Disease Consultant
221	Phenazopyridine HCl: Tablet: 200 mg	Urology Society
222	Phenobarbital: Syrup	Paed Society
223	Phenobarbitone: Injection: 200 mg/mL	Paropakar Maternity and Women's Hospital
224	Phenoxybenzamine: Injection	Cardiology Society
225	Phenytoin: Syrup	Paed Society
226	Podophyllin Resin: Topical Solution: 25%	Dermatology Society
227	Podophyllum Resin: Topical Solution: 25%	Infectious Disease Consultant
228	Polydeoxyribonucleotide (PDRN): Injectable Solution: 5.625 mg/3 mL	Dermatology Society
229	Posaconazole: Tablet/Suspension	Infectious Disease Consultant
230	Potassium Binders (Calcium Polystyrene Sulfonate): Powder	Paed Society
231	Potassium Phosphate + Sodium Phosphate: Injection	Critical Care Society
232	Povidone Iodine: Eye Drops	Ophthalmology Consultant-KMC
233	Prednisolone: Syrup: 15 mg/5 mL	Paed Society
234	Pregabalin: Capsule: 75 mg, 150 mg	Cancer pain Consultant-Clincal Pharmacist
235	Premixed Insulin: Injection: 30/70, 50/50	Endocrine Society
236	Premixed Insulin: Injection: 30/70, 50/50	Endocriology Consultant-Consultant Endocrionlogist
237	Pretomanid: Tablet: 200 mg	National Tuberculosis Center
238	Procainamide: Tablet/Injection	From Pharmacist
239	Proguanil: Tablet	Infectious Disease Consultant
240	Propranolol 10 mg (20/40- Listed)	Psychiatry Society

241	Propranolol: Tablet: 10 mg, 20 mg, 40 mg	Endocrine Society
242	Propylthiouracil: Tablet: 50 mg	Endocrine Society
243	Prostaglandin E1: Injection: 500 micrograms/mL	Paropakar Maternity and Women's Hospital
244	Prostaglandin E1/E2: Solution for Injection: 0.5 mg/mL	Cardiology Society
245	Pyrantel: Tablet/Suspension	Infectious Disease Consultant
246	Pyrazinamide: Tablet	Infectious Disease Consultant
247	Pyridostigmine: Tablet: 60 mg; Extended Release: 180 mg	Neuro Consultant-Bansbari Neuro Hosp & National N H
248	Pyrimethamine: Tablet	Infectious Disease Consultant
249	Rabies Vaccine: Injection	Infectious Disease Consultant
250	Relugolix: Tablet: 120 mg	Oncology Society
251	Repaglinide: Tablet: 0.5 mg, 1 mg	Endocrine Society
252	Rifampicin: Capsule/Tablet	Infectious Disease Consultant
253	Rifapentine: Tablet	Infectious Disease Consultant
254	Rifaximin: Tablet: 550 mg	From TUTH
255	Riociguat: Tablet: 1 mg	Cardiology Society
256	Ripasudil: Eye Drops	Ophthalmology Society
257	Rituximab: Injection: 100 mg, 500 mg	Oncology Consultant-Medical Oncologist
258	Rivaroxaban: Tablet: 20 mg	Cardiology Society
259	Rizatriptan: Tablet: 5 mg, 10 mg	Neuro Consultant-Bansbari Neuro Hosp & National N H
260	Rocuronium: Injection: 10 mg, 50 mg	Anesthesia Society
261	Ropivacaine: Solution for Injection: 0.2%, 0.75%	Anesthesia Society
262	RUTF (Ready-to-Use Therapeutic Food)	Family Welfare Division
263	SARS-CoV-2 Vaccine: Injection	Infectious Disease Consultant
264	Sertraline: Tablet: 50 mg	Psychiatry Society
265	Sevelamer Carbonate: Tablet	Internal Medicine
266	Sevelamer: Tablet: 400 mg, 800 mg	Nephro Society
267	Sevoflurane: Inhalation	Anesthesia Society
268	Sildenafil: Injection: 10 mg	Cardiology Society
269	Sitagliptin: Tablet	Internal Medicine
270	Sodium Bicarbonate: Syrup; Tablet: 500 mg, 1 g	Paed Society
271	Sodium Chloride: Injection: 3%	ENT Society
272	Sodium Thiosulphate: Injection	Antidote and other substances Consultant-

273	Sodium Valproate: Tablet: 200 mg, 300 mg, 500 mg	Psychiatry Society
274	Sofosbuvir + Velpatasvir: Tablet	Infectious Disease Consultant
275	Sorafenib: Tablet: 200 mg, 400 mg	Oncology Society
276	Specialized Formula for Phenylketonuria (PKU)	Paropakar Maternity and Women's Hospital
277	Succimer: Capsule: 100 mg	Antidote and other substances Consultant-Assoc. Prof. PU
278	Sugammadex: Injection	Anesthesia Society
279	Sulfadiazine: Tablet	Infectious Disease Consultant
280	Sumatriptan: Tablet: 50 mg	Neuro Consultant-Bansbari Neuro Hosp & National N H
281	Surfactant Bovine Lipid Extract: Injection	Paropakar Maternity and Women's Hospital
282	Tacrolimus: Eye Ointment	Ophthalmology Society
283	Tacrolimus: Tablet	Internal Medicine
284	Teicoplanin: Injection	Internal Medicine
285	Temozolomide: Tablet: 100 mg, 250 mg	Oncology Society
286	Tenecteplase: Injection	From Doctor
287	Terbinafine: Tablet/Cream	Infectious Disease Consultant
288	Terlipressin: Injection: 1 mg, 2 mg	Gastroenterology Society
289	Testosterone	Endocriology Consultant-Consultant Endocrionlogist
290	Thalidomide: Capsule: 50 mg	Oncology Consultant-Medical Oncologist
291	Thiamine: Injection: 100 mg	From TUTH
292	Thyroxine (Levothyroxine): Injection: 100 mcg	Critical Care Society
293	Ticagrelor or Cangrelor	Cardiology Consultant- KMC
294	Ticagrelor: Tablet 90/180 mg	Cardiology Society
295	Ticagrelor: Tablet: 90 mg, 180 mg	Neurointerventionist Consultant-Bansbari Neuro Hosp
296	Tigecycline: Injection	NATG Society
297	Tinidazole: Tablet	From Pharmacist
298	Tirofiban: Injection	Neurointerventionist Consultant-Bansbari Neuro Hosp
299	Tizanidine: Tablet	Nepal Orthopedic Association
300	Tofacitinib: Topical Ointment/Cream: 2%	Dermatology Society

301	Topiramate: Tablet (Intermediate Release)	From Pharmacist
302	Torsemide: Tablet	Internal Medicine
303	Tramadol: Tablet: 50 mg; Injection: 50 mg/mL	Cancer pain Consultant-Clincal Pharmacist
304	Trimetazidine: Tablet	Cardiology Consultant- KMC
305	Trypan Blue (Auroblue): Injection: 1 mL	Ophthalmology Society
306	Tuberculin Purified Protein Derivative (PPD): Injection	Infectious Disease Consultant
307	Typhoid Vaccine: Injection	Infectious Disease Consultant
308	Valaciclovir: Tablet	Infectious Disease Consultant
309	Valganciclovir: Tablet	Oncology Society
310	Valproic Acid: Injection: 100 mg/mL (3 mL, 4 mL, 10 mL ampoules)	Neuro Consultant-Bansbari Neuro Hosp
311	Valsartan/Sacubitril: Tablet	Cardiology Consultant-Assos. Prof @ KMC
312	Varenicline: Tablet	
313	Varicella Vaccine: Injection	Infectious Disease Consultant
314	Varicella Zoster Immunoglobulin: Injection	Paropakar Maternity and Women's Hospital
315	Vasopressin: Injection: 20 IU	Cardiology Society
316	Venetoclax: Tablet: 100 mg	From TUTH
317	Vinorelbine: Capsule: 20 mg, 30 mg, 80 mg; Injection: 10 mg/mL	Oncology Consultant-Medical Oncologist
318	Vitamin D: Injection	KMC
319	Vitamin E: Liquid (Oral)	Paropakar Maternity and Women's Hospital
320	Vitamin K: Injection	From Pharmacist
321	Vonoprazan: Tablet	Gastroenterology Society
322	Voriconazole: Tablet/Injection	Infectious Disease Consultant

ANNEX VI

Index

S. No. Medicine Name

1. abacavir
2. abacavir + lamivudine
3. abiraterone
4. acamprosate calcium
5. acetazolamide
6. acetic acid
7. acetylcysteine
8. acetylsalicylic acid (aspirin)
9. aciclovir
10. albendazole
11. albumin, human
12. alcohol based hand rub
13. allopurinol
14. all-trans retinoid acid
15. amidotrizoate
16. amikacin
17. amiodarone
18. amitriptyline
19. amlodipine
20. amlodipine + losartan
21. amoxicillin
22. amoxicillin + clavulanic acid
23. amphotericin B
24. ampicillin
25. Anti-D immunoglobulin
26. Anti-rabies hyperimmune serum
27. Anti-tetanus immunoglobulin
28. apixaban
29. aprepitant
30. arsenic trioxide
31. artemether + lumefantrine
32. artesunate
33. ascorbic acid

34. atazanavir + ritonavir
35. atorvastatin
36. atovaquone + proguanil
37. atracurium
38. atropine
39. azathioprine
40. azithromycin
41. baclofen
42. barium sulfate
43. BCG (Vaccine)
44. beclomethasone
45. bedaquiline
46. bendamustine
47. benzathine benzylpenicillin
48. benzocaine
49. benzoic acid + salicylic acid
50. benzoyl peroxide
51. benzyl benzoate
52. benzylpenicillin (penicillin G)
53. betamethasone
54. bicalutamide
55. bisacodyl
56. bisoprolol
57. bleomycin
58. bortezomib
59. budesonide + formoterol
60. bupivacaine
61. buprenorphine
62. caffeine citrate
63. calamine
64. calcium
65. calcium folinate (calcium leucovorin)
66. calcium gluconate
67. capecitabine
68. carbamazepine
69. carbetocin
70. carbimazole
71. carboplatin

72. cefazolin
73. cefixime
74. cefotaxime
75. ceftazidime
76. ceftriaxone
77. cephalexin
78. charcoal, activated
79. chlorambucil
80. chloramphenicol
81. chlordiazepoxide
82. chlorhexidine
83. chlorine based compound
84. chloroquine
85. chlorpromazine
86. ciclosporin (cyclosporine)
87. ciprofloxacin
88. cisplatin
89. clarithromycin
90. clindamycin
91. clofazimine
92. clomifene
93. clonazepam
94. clonidine
95. clopidogrel
96. clotrimazole
97. cloxacillin
98. coagulation factor IX
99. coagulation factor VIII
100. codeine
101. colchicine
102. colecalciferol
103. colistin
104. compound solution of sodium lactate (ringer's)
105. condoms
106. copper-containing devices
107. cyanocobalamin
108. cyclophosphamide
109. cycloserine

110. cytarabine
111. dacarbazine
112. daclatasvir + sofosbuvir
113. dactinomycin
114. dapagliflozin
115. dapsone
116. darunavir
117. dasatinib
118. daunorubicin
119. deferasirox
120. deferiprone
121. deferoxamine
122. delamanid
123. desmopressin
124. dexamethasone
125. diazepam
126. diclofenac sodium
127. diethylcarbamazine
128. digoxin
129. dihydroartemisinin + piperaquine phosphate
130. dimercaprol
131. diphtheria antitoxin (immunoglobulin)
132. diphtheria, tetanus, pertussis, hepatitis B (pentavalent) (Vaccine)
133. dobutamine
134. docetaxel
135. dolutegravir
136. dolutegravir + lamivudine + tenofovir
137. domperidone
138. dopamine
139. doxorubicin
140. doxycycline
141. drotaverine hydrochloride
142. emtricitabine + tenofovir
143. enalapril
144. enoxaparin
145. entecavir
146. ephedrine
147. epinephrine (adrenaline)

148. epirubicin
149. equine rabies immunoglobulin (erig)
150. erythromycin
151. erythropoietin (epo)
152. escitalopram
153. ethambutol
154. ethambutol + isoniazid + pyrazinamide + rifampicin
155. ethambutol + isoniazid + rifampicin
156. ethanol (rectified spirit)
157. ethinylestradiol
158. ethinylestradiol + levonorgestrel
159. ethinylestradiol + norethisterone
160. ethionamide
161. etoposide
162. f 100 therapeutic milk
163. f 75 therapeutic milk
164. fenofibrate
165. fentanyl
166. ferrous salt
167. ferrous salt + folic acid
168. fexofenadine
169. filgrastim
170. fluconazole
171. flucytosine
172. fludrocortisone
173. fluorescein
174. fluoride
175. fluorouracil
176. fluoxetine
177. fluphenazine
178. flurbiprofen
179. folic acid
180. fomepizole
181. fosfomycin
182. furosemide
183. fusidic acid
184. ganciclovir
185. gefitinib

186. gemcitabine
187. gentamicin
188. gliclazide
189. glipizide
190. glucose
191. glucose with sodium chloride
192. glutaraldehyde
193. glycerol
194. glyceryl trinitrate
195. glycopyrrolate
196. Haemophilus influenzae type b (Vaccine)
197. haloperidol
198. heparin sodium
199. hepatitis A (Vaccine)
200. hepatitis B (Vaccine)
201. human papilloma vaccine (HPV)
202. hydralazine
203. hydrochlorothiazide
204. hydrocortisone
205. hydroxychloroquine
206. hydroxyurea (hydroxycarbamide)
207. hyoscine butylbromide
208. hypoclorous acid
209. ibuprofen
210. ifosfamide + mesna
211. imatinib
212. influenza (seasonal) (Vaccine)
213. insulin (rapid acting)
214. insulin (soluble)
215. insulin glargine
216. intermediate acting insulin (NPH)
217. intrauterine device with progesterone
218. iohexol
219. ipratropium bromide
220. irinotecan
221. iron sucrose
222. isoflurane
223. isoniazid

224. isoniazid + pyrazinamide + rifampicin
225. isoniazid + rifampicin
226. isoprenaline
227. isosorbide dinitrate
228. ispaghula husk
229. itraconazole
230. ivermectin
231. japanese encephalitis vaccine
232. ketamine
233. labetalol
234. lactulose
235. lamivudine (3TC)
236. lamivudine + tenofovir
237. lamivudine + zidovudine
238. lamotrigine
239. l-asparaginase
240. latanoprost
241. ledipasvir + sofosbuvir
242. lenalidomide
243. letrozole
244. levetiracetam
245. levocetirizine
246. levodopa + carbidopa
247. levofloxacin
248. levonorgestrel
249. levonorgestrel releasing implant
250. levothyroxine
251. lidocaine (lignocaine)
252. lidocaine (lignocaine) + epinephrine (adrenaline)
253. linezolid
254. lithium carbonate
255. loperamide
256. lopinavir + ritonavir (LPV/r)
257. lorazepam
258. losartan
259. lugol's iodine
260. magnesium sulfate
261. mannitol

262. measles (Vaccine)
263. measles rubella (MR) (Vaccine)
264. mebendazole
265. medroxyprogesterone acetate
266. mefloquine
267. meglumine iotroxate
268. melphalan
269. meningococcal meningitis (Vaccine)
270. mercaptopurine
271. meropenem
272. mesna
273. metformin
274. methadone
275. methotrexate
276. methyldopa
277. methylergometrine
278. methylprednisolone
279. methylthioninium chloride (methylene blue)
280. metoclopramide
281. metoprolol
282. metronidazole
283. midazolam
284. mifepristone + misoprostol
285. miltefosine
286. misoprostol
287. mitomycin
288. mometasone furoate
289. morphine
290. moxifloxacin
291. multiple micronutrient powder
292. multiple micronutrient supplement
293. mumps (Vaccine)
294. mupirocin
295. naloxone
296. natamycin
297. neostigmine
298. nevirapine (NVP)
299. niclosamide

300. nicotine replacement therapy (NRT)
301. nifedipine
302. nitrofurantoin
303. nitrous oxide
304. norepinephrine (noradrenaline)
305. norethisterone
306. nystatin
307. octreotide
308. ofloxacin
309. olanzapine
310. omeprazole
311. ondansetron
312. oral rehydration salts
313. oseltamivir
314. oxaliplatin
315. oxygen
316. oxymetazoline
317. oxytocin
318. paclitaxel
319. p-aminosalicylic acid
320. pantoprazole
321. paracetamol
322. paromomycin
323. pembrolizumab
324. peritoneal dialysis solution
325. permethrin
326. pethidine
327. pheniramine
328. phenobarbital
329. phenoxymethyl penicillin (penicillin V)
330. phenytoin
331. phytomenadione
332. pilocarpine
333. piperacillin + tazobactam
334. pneumococcal (Vaccine)
335. podophyllotoxin
336. poliomyelitis (inactivated) (Vaccine)
337. poliomyelitis (oral) (Vaccine)

338. polygeline
339. polymyxin B
340. polyvenom antisnake serum
341. potassium chloride
342. potassium ferric hexacyanoferrate
343. povidone iodine
344. pralidoxime
345. praziquantel
346. prazosin
347. prednisolone
348. premixed insulin
349. pretomanid
350. primaquine
351. procaine benzylpenicillin
352. procarbazine
353. proparacaine
354. propofol
355. propranolol
356. propylthiouracil
357. prostaglandin E1
358. protamine sulfate
359. pyrazinamide
360. pyridostigmine
361. pyridoxine
362. rabies vaccine, freeze dried
363. raltegravir
364. ramipril
365. ranitidine
366. ready to use therapeutic products
367. retinol
368. ribavirin
369. riboflavin
370. rifabutin
371. rifampicin
372. rifapentine
373. ring pessary
374. risperidone
375. ritonavir

376. rituximab
377. rotavirus (Vaccine)
378. rubella (Vaccine)
379. salbutamol
380. salicylic acid
381. secnidazole
382. semaglutide
383. sevoflurane
384. silicon ring pessary
385. silver sulfadiazine
386. sodium bicarbonate
387. sodium bicarbonate + glycerin
388. sodium calcium edetate
389. sodium chloride
390. sodium nitrite
391. sodium nitroprusside
392. sofosbuvir
393. sofosbuvir + velpatasvir
394. spironolactone
395. succimer
396. sulfadoxine + pyrimethamine
397. sulfamethoxazole + trimethoprim
398. sulfasalazine
399. sumatriptan
400. surfactant
401. suxamethonium (succinylcholine)
402. tamoxifen
403. tenecteplase
404. tenofovir alafenamide
405. tenofovir disoproxil fumarate (TDF)
406. terbutaline
407. testosterone
408. tetanus antitoxin (immunoglobulin)
409. tetanus diphtheria (Td) (Vaccine)
410. tetanus toxoid (Vaccine)
411. tetracaine
412. tetracycline
413. thalidomide

414. thiamine
415. timolol
416. tinidazole
417. tranexamic acid
418. trihexyphenidyl (benzhexol)
419. tropicamide
420. tuberculin, purified protein derivative (PPD)
421. typhoid (Vaccine)
422. urea
423. valganciclovir
424. valproic acid
425. vancomycin
426. vecuronium
427. verapamil
428. vinblastine
429. vincristine
430. warfarin
431. water for injection
432. yellow fever (Vaccine)
433. zidovudine (ZV or AZT)
434. zinc oxide
435. zinc sulfate
436. zoledronic acid

National List of Essential Medicines first published in 1986

First revision	1992
Second revision	1997
Third revision	2002
Fourth revision	2011
Fifth revision	2016
Sixth revision	2021

Technical Support by:

HELEN KELLER INTL

World Health Organization
Nepal